false 2021 Q2 IDEXX LABORATORIES INC /DE 0000874716--12-31 P1Y 6 1 1 1 6 1 1 1 6 1 1 1 6 1 1 1 us-gaap:AccruedLiabilitiesCurrent us-gaap:AccruedLiabilitiesCurrent 0000874716 2021-01-01 2021-06-30 xbrli:shares 0000874716 2021-07-26 iso4217:USD 0000874716 2021-06-30 0000874716 2020-12-31 iso4217:USD xbrli:shares 0000874716 us-gaap:ProductMember 2021-04-01 2021-06-30 0000874716 us-gaap:ProductMember 2020-04-01 2020-06-30 0000874716 us-gaap:ProductMember 2021-01-01 2021-06-30 0000874716 us-gaap:ProductMember 2020-01-01 2020-06-30 0000874716 us-gaap:ServiceMember 2021-04-01 2021-06-30 0000874716 us-gaap:ServiceMember 2020-04-01 2020-06-30 0000874716 us-gaap:ServiceMember 2021-01-01 2021-06-30 0000874716 us-gaap:ServiceMember 2020-01-01 2020-06-30 0000874716 2021-04-01 2021-06-30 0000874716 2020-04-01 2020-06-30 0000874716 2020-01-01 2020-06-30 0000874716 2021-03-31 0000874716 2019-12-31 0000874716 2020-03-31 0000874716 2020-06-30 0000874716 us-gaap:CommonStockMember 2020-12-31 0000874716 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000874716 idxx:DeferredStockUnitsMember 2020-12-31 0000874716 us-gaap:RetainedEarningsMember 2020-12-31 0000874716 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000874716 us-gaap:TreasuryStockMember 2020-12-31 0000874716 us-gaap:NoncontrollingInterestMember 2020-12-31 0000874716 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000874716 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0000874716 2021-01-01 2021-03-31 0000874716 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000874716 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0000874716 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000874716 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000874716 idxx:DeferredStockUnitsMember 2021-01-01 2021-03-31 0000874716 us-gaap:CommonStockMember 2021-03-31 0000874716 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000874716 idxx:DeferredStockUnitsMember 2021-03-31 0000874716 us-gaap:RetainedEarningsMember 2021-03-31 0000874716 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000874716 us-gaap:TreasuryStockMember 2021-03-31 0000874716 us-gaap:NoncontrollingInterestMember 2021-03-31 0000874716 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000874716 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0000874716 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0000874716 us-gaap:TreasuryStockMember 2021-04-01 2021-06-30 0000874716 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000874716 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000874716 idxx:DeferredStockUnitsMember 2021-04-01 2021-06-30 0000874716 us-gaap:CommonStockMember 2021-06-30 0000874716 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000874716 idxx:DeferredStockUnitsMember 2021-06-30 0000874716 us-gaap:RetainedEarningsMember 2021-06-30 0000874716 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000874716 us-gaap:TreasuryStockMember 2021-06-30 0000874716 us-gaap:NoncontrollingInterestMember 2021-06-30 0000874716 us-gaap:CommonStockMember 2019-12-31 0000874716 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000874716 idxx:DeferredStockUnitsMember 2019-12-31 0000874716 us-gaap:RetainedEarningsMember 2019-12-31 0000874716 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000874716 us-gaap:TreasuryStockMember 2019-12-31 0000874716 us-gaap:NoncontrollingInterestMember 2019-12-31 0000874716 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-12-31 0000874716 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0000874716 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000874716 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0000874716 2020-01-01 2020-03-31 0000874716 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000874716 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0000874716 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000874716 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000874716 idxx:DeferredStockUnitsMember 2020-01-01 2020-03-31 0000874716 us-gaap:CommonStockMember 2020-03-31 0000874716 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000874716 idxx:DeferredStockUnitsMember 2020-03-31 0000874716 us-gaap:RetainedEarningsMember 2020-03-31 0000874716 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000874716 us-gaap:TreasuryStockMember 2020-03-31 0000874716 us-gaap:NoncontrollingInterestMember 2020-03-31 0000874716 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000874716 us-gaap:NoncontrollingInterestMember 2020-04-01 2020-06-30 0000874716 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0000874716 us-gaap:TreasuryStockMember 2020-04-01 2020-06-30 0000874716 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000874716 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000874716 idxx:DeferredStockUnitsMember 2020-04-01 2020-06-30 0000874716 us-gaap:CommonStockMember 2020-06-30 0000874716 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000874716 idxx:DeferredStockUnitsMember 2020-06-30 0000874716 us-gaap:RetainedEarningsMember 2020-06-30 0000874716 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000874716 us-gaap:TreasuryStockMember 2020-06-30 0000874716 us-gaap:NoncontrollingInterestMember 2020-06-30 0000874716 srt:MinimumMember 2021-01-01 2021-06-30 0000874716 srt:MaximumMember 2021-01-01 2021-06-30 0000874716 srt:MinimumMember idxx:ExtendedWarrantiesAndPostContractSupportMember 2021-01-01 2021-06-30 0000874716 idxx:ExtendedWarrantiesAndPostContractSupportMember srt:MaximumMember 2021-01-01 2021-06-30 0000874716 idxx:ExtendedWarrantiesAndPostContractSupportMember 2021-01-01 2021-06-30 0000874716 idxx:ExtendedWarrantiesAndPostContractSupportMember 2020-12-31 0000874716 idxx:ExtendedWarrantiesAndPostContractSupportMember 2021-04-01 2021-06-30 0000874716 idxx:ExtendedWarrantiesAndPostContractSupportMember 2021-06-30 xbrli:pure 0000874716 2021-07-01 idxx:ExtendedWarrantiesAndPostContractSupportMember 2021-06-30 0000874716 2022-01-01 idxx:ExtendedWarrantiesAndPostContractSupportMember 2021-06-30 0000874716 2023-01-01 idxx:ExtendedWarrantiesAndPostContractSupportMember 2021-06-30 0000874716 idxx:ExtendedWarrantiesAndPostContractSupportMember 2024-01-01 2021-06-30 0000874716 2025-01-01 idxx:ExtendedWarrantiesAndPostContractSupportMember 2021-06-30 0000874716 idxx:UpFrontCustomerLoyaltyProgramsMember 2020-12-31 0000874716 idxx:UpFrontCustomerLoyaltyProgramsMember 2021-04-01 2021-06-30 0000874716 idxx:UpFrontCustomerLoyaltyProgramsMember 2021-01-01 2021-06-30 0000874716 idxx:UpFrontCustomerLoyaltyProgramsMember 2021-06-30 0000874716 idxx:VolumeCommitmentProgramsMember 2020-12-31 0000874716 idxx:VolumeCommitmentProgramsMember 2021-04-01 2021-06-30 0000874716 idxx:VolumeCommitmentProgramsMember 2021-01-01 2021-06-30 0000874716 idxx:VolumeCommitmentProgramsMember 2021-06-30 0000874716 idxx:UpFrontCustomerLoyaltyProgramsAndVolumeCommitmentProgramsMember 2021-06-30 0000874716 idxx:UpFrontCustomerLoyaltyProgramsAndVolumeCommitmentProgramsMember 2021-07-01 2021-06-30 0000874716 idxx:UpFrontCustomerLoyaltyProgramsAndVolumeCommitmentProgramsMember 2022-01-01 2021-06-30 0000874716 idxx:UpFrontCustomerLoyaltyProgramsAndVolumeCommitmentProgramsMember 2023-01-01 2021-06-30 0000874716 idxx:UpFrontCustomerLoyaltyProgramsAndVolumeCommitmentProgramsMember 2024-01-01 2021-06-30 0000874716 idxx:UpFrontCustomerLoyaltyProgramsAndVolumeCommitmentProgramsMember 2025-01-01 2021-06-30 0000874716 idxx:InstrumentRebateProgramsMember 2020-12-31 0000874716 idxx:InstrumentRebateProgramsMember 2021-04-01 2021-06-30 0000874716 idxx:InstrumentRebateProgramsMember 2021-01-01 2021-06-30 0000874716 idxx:InstrumentRebateProgramsMember 2021-06-30 0000874716 idxx:InstrumentRebateProgramsMember 2021-07-01 2021-06-30 0000874716 idxx:InstrumentRebateProgramsMember 2022-01-01 2021-06-30 0000874716 2023-01-01 idxx:InstrumentRebateProgramsMember 2021-06-30 0000874716 idxx:InstrumentRebateProgramsMember 2024-01-01 2021-06-30 0000874716 idxx:InstrumentRebateProgramsMember 2025-01-01 2021-06-30 0000874716 idxx:OperatingtypeReagentRentalProgramsMember 2021-04-01 2021-06-30 0000874716 idxx:OperatingtypeReagentRentalProgramsMember 2021-01-01 2021-06-30 0000874716 idxx:OperatingtypeReagentRentalProgramsMember 2020-04-01 2020-06-30 0000874716 idxx:OperatingtypeReagentRentalProgramsMember 2020-01-01 2020-06-30 0000874716 idxx:ReagentRentalProgramsMember 2021-06-30 0000874716 idxx:ReagentRentalProgramsMember 2021-07-01 2021-06-30 0000874716 idxx:ReagentRentalProgramsMember 2022-01-01 2021-06-30 0000874716 idxx:ReagentRentalProgramsMember 2023-01-01 2021-06-30 0000874716 idxx:ReagentRentalProgramsMember 2024-01-01 2021-06-30 0000874716 idxx:ReagentRentalProgramsMember 2025-01-01 2021-06-30 0000874716 idxx:CagDiagnosticsRecurringRevenueMember idxx:CagSegmentMember 2021-04-01 2021-06-30 0000874716 idxx:CagDiagnosticsRecurringRevenueMember idxx:CagSegmentMember 2020-04-01 2020-06-30 0000874716 idxx:CagDiagnosticsRecurringRevenueMember idxx:CagSegmentMember 2021-01-01 2021-06-30 0000874716 idxx:CagDiagnosticsRecurringRevenueMember idxx:CagSegmentMember 2020-01-01 2020-06-30 0000874716 idxx:VetlabConsumablesMember idxx:CagSegmentMember 2021-04-01 2021-06-30 0000874716 idxx:VetlabConsumablesMember idxx:CagSegmentMember 2020-04-01 2020-06-30 0000874716 idxx:VetlabConsumablesMember idxx:CagSegmentMember 2021-01-01 2021-06-30 0000874716 idxx:VetlabConsumablesMember idxx:CagSegmentMember 2020-01-01 2020-06-30 0000874716 idxx:CagSegmentMember idxx:RapidAssayProductsMember 2021-04-01 2021-06-30 0000874716 idxx:CagSegmentMember idxx:RapidAssayProductsMember 2020-04-01 2020-06-30 0000874716 idxx:CagSegmentMember idxx:RapidAssayProductsMember 2021-01-01 2021-06-30 0000874716 idxx:CagSegmentMember idxx:RapidAssayProductsMember 2020-01-01 2020-06-30 0000874716 idxx:ReferenceLaboratoryDiagnosticAndConsultingServicesMember idxx:CagSegmentMember 2021-04-01 2021-06-30 0000874716 idxx:ReferenceLaboratoryDiagnosticAndConsultingServicesMember idxx:CagSegmentMember 2020-04-01 2020-06-30 0000874716 idxx:ReferenceLaboratoryDiagnosticAndConsultingServicesMember idxx:CagSegmentMember 2021-01-01 2021-06-30 0000874716 idxx:ReferenceLaboratoryDiagnosticAndConsultingServicesMember idxx:CagSegmentMember 2020-01-01 2020-06-30 0000874716 idxx:CagDiagnosticsServiceAndAccessoriesMember idxx:CagSegmentMember 2021-04-01 2021-06-30 0000874716 idxx:CagDiagnosticsServiceAndAccessoriesMember idxx:CagSegmentMember 2020-04-01 2020-06-30 0000874716 idxx:CagDiagnosticsServiceAndAccessoriesMember idxx:CagSegmentMember 2021-01-01 2021-06-30 0000874716 idxx:CagDiagnosticsServiceAndAccessoriesMember idxx:CagSegmentMember 2020-01-01 2020-06-30 0000874716 idxx:CagDiagnosticCaptailVetlabInstrumentsMember idxx:CagSegmentMember 2021-04-01 2021-06-30 0000874716 idxx:CagDiagnosticCaptailVetlabInstrumentsMember idxx:CagSegmentMember 2020-04-01 2020-06-30 0000874716 idxx:CagDiagnosticCaptailVetlabInstrumentsMember idxx:CagSegmentMember 2021-01-01 2021-06-30 0000874716 idxx:CagDiagnosticCaptailVetlabInstrumentsMember idxx:CagSegmentMember 2020-01-01 2020-06-30 0000874716 idxx:CagSegmentMember idxx:VeterinarySoftwareServicesAndDiagnosticImagingSystemsMember 2021-04-01 2021-06-30 0000874716 idxx:CagSegmentMember idxx:VeterinarySoftwareServicesAndDiagnosticImagingSystemsMember 2020-04-01 2020-06-30 0000874716 idxx:CagSegmentMember idxx:VeterinarySoftwareServicesAndDiagnosticImagingSystemsMember 2021-01-01 2021-06-30 0000874716 idxx:CagSegmentMember idxx:VeterinarySoftwareServicesAndDiagnosticImagingSystemsMember 2020-01-01 2020-06-30 0000874716 idxx:CagSegmentMember 2021-04-01 2021-06-30 0000874716 idxx:CagSegmentMember 2020-04-01 2020-06-30 0000874716 idxx:CagSegmentMember 2021-01-01 2021-06-30 0000874716 idxx:CagSegmentMember 2020-01-01 2020-06-30 0000874716 idxx:WaterSegmentMember 2021-04-01 2021-06-30 0000874716 idxx:WaterSegmentMember 2020-04-01 2020-06-30 0000874716 idxx:WaterSegmentMember 2021-01-01 2021-06-30 0000874716 idxx:WaterSegmentMember 2020-01-01 2020-06-30 0000874716 idxx:LpdSegmentMember 2021-04-01 2021-06-30 0000874716 idxx:LpdSegmentMember 2020-04-01 2020-06-30 0000874716 idxx:LpdSegmentMember 2021-01-01 2021-06-30 0000874716 idxx:LpdSegmentMember 2020-01-01 2020-06-30 0000874716 idxx:OtherSegmentMember 2021-04-01 2021-06-30 0000874716 idxx:OtherSegmentMember 2020-04-01 2020-06-30 0000874716 idxx:OtherSegmentMember 2021-01-01 2021-06-30 0000874716 idxx:OtherSegmentMember 2020-01-01 2020-06-30 0000874716 country:US 2021-04-01 2021-06-30 0000874716 country:US 2020-04-01 2020-06-30 0000874716 country:US 2021-01-01 2021-06-30 0000874716 country:US 2020-01-01 2020-06-30 0000874716 us-gaap:EMEAMember 2021-04-01 2021-06-30 0000874716 us-gaap:EMEAMember 2020-04-01 2020-06-30 0000874716 us-gaap:EMEAMember 2021-01-01 2021-06-30 0000874716 us-gaap:EMEAMember 2020-01-01 2020-06-30 0000874716 srt:AsiaPacificMember 2021-04-01 2021-06-30 0000874716 srt:AsiaPacificMember 2020-04-01 2020-06-30 0000874716 srt:AsiaPacificMember 2021-01-01 2021-06-30 0000874716 srt:AsiaPacificMember 2020-01-01 2020-06-30 0000874716 country:CA 2021-04-01 2021-06-30 0000874716 country:CA 2020-04-01 2020-06-30 0000874716 country:CA 2021-01-01 2021-06-30 0000874716 country:CA 2020-01-01 2020-06-30 0000874716 srt:LatinAmericaMember 2021-04-01 2021-06-30 0000874716 srt:LatinAmericaMember 2020-04-01 2020-06-30 0000874716 srt:LatinAmericaMember 2021-01-01 2021-06-30 0000874716 srt:LatinAmericaMember 2020-01-01 2020-06-30 0000874716 srt:MinimumMember 2021-06-30 0000874716 srt:MaximumMember 2021-06-30 0000874716 idxx:EzyVetMember 2021-04-01 2021-06-30 0000874716 idxx:EzyVetMember 2021-06-30 0000874716 us-gaap:CustomerRelatedIntangibleAssetsMember idxx:EzyVetMember 2021-06-30 0000874716 us-gaap:CustomerRelatedIntangibleAssetsMember idxx:EzyVetMember 2021-04-01 2021-06-30 0000874716 us-gaap:TechnologyBasedIntangibleAssetsMember idxx:EzyVetMember 2021-06-30 0000874716 us-gaap:TechnologyBasedIntangibleAssetsMember idxx:EzyVetMember 2021-04-01 2021-06-30 0000874716 idxx:EzyVetMember us-gaap:TradeNamesMember 2021-06-30 0000874716 idxx:EzyVetMember us-gaap:TradeNamesMember 2021-04-01 2021-06-30 0000874716 us-gaap:NoncompeteAgreementsMember idxx:EzyVetMember 2021-06-30 0000874716 us-gaap:NoncompeteAgreementsMember idxx:EzyVetMember 2021-04-01 2021-06-30 0000874716 country:CH idxx:ReferenceLaboratoryMember 2021-01-01 2021-03-31 0000874716 country:CH idxx:ReferenceLaboratoryMember 2021-03-31 0000874716 country:CH idxx:ReferenceLaboratoryMember us-gaap:CustomerRelationshipsMember 2021-03-31 0000874716 country:CH idxx:ReferenceLaboratoryMember us-gaap:CustomerRelationshipsMember 2021-01-01 2021-03-31 0000874716 idxx:FinancialAssetGreaterThan60DaysPastDueMember 2021-06-30 0000874716 idxx:FinancialAssetGreaterThan60DaysPastDueMember 2020-12-31 0000874716 idxx:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleIncludingPortionAttributableToNoncontrollingInterestMember 2020-12-31 0000874716 idxx:AccumulatedNetGainLossFromCashFlowHedgesForeignCurrencyExchangeContractsIncludingPortionAttributableToNoncontrollingInterestMember 2020-12-31 0000874716 idxx:AccumulatedNetGainLossFromNetInvestmentHedgesEuroDenominatedNotesIncludingPortionAttributableToNoncontrollingInterestMember 2020-12-31 0000874716 idxx:AccumulatedNetGainLossFromNetInvestmentHedgesCrossCurrencySwapsIncludingPortionAttributableToNoncontrollingInterestMember 2020-12-31 0000874716 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2020-12-31 0000874716 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2020-12-31 0000874716 idxx:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleIncludingPortionAttributableToNoncontrollingInterestMember 2021-01-01 2021-06-30 0000874716 idxx:AccumulatedNetGainLossFromCashFlowHedgesForeignCurrencyExchangeContractsIncludingPortionAttributableToNoncontrollingInterestMember 2021-01-01 2021-06-30 0000874716 idxx:AccumulatedNetGainLossFromNetInvestmentHedgesEuroDenominatedNotesIncludingPortionAttributableToNoncontrollingInterestMember 2021-01-01 2021-06-30 0000874716 idxx:AccumulatedNetGainLossFromNetInvestmentHedgesCrossCurrencySwapsIncludingPortionAttributableToNoncontrollingInterestMember 2021-01-01 2021-06-30 0000874716 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2021-01-01 2021-06-30 0000874716 idxx:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleIncludingPortionAttributableToNoncontrollingInterestMember 2021-06-30 0000874716 idxx:AccumulatedNetGainLossFromCashFlowHedgesForeignCurrencyExchangeContractsIncludingPortionAttributableToNoncontrollingInterestMember 2021-06-30 0000874716 idxx:AccumulatedNetGainLossFromNetInvestmentHedgesEuroDenominatedNotesIncludingPortionAttributableToNoncontrollingInterestMember 2021-06-30 0000874716 idxx:AccumulatedNetGainLossFromNetInvestmentHedgesCrossCurrencySwapsIncludingPortionAttributableToNoncontrollingInterestMember 2021-06-30 0000874716 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2021-06-30 0000874716 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-06-30 0000874716 idxx:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleIncludingPortionAttributableToNoncontrollingInterestMember 2019-12-31 0000874716 idxx:AccumulatedNetGainLossFromCashFlowHedgesForeignCurrencyExchangeContractsIncludingPortionAttributableToNoncontrollingInterestMember 2019-12-31 0000874716 idxx:AccumulatedNetGainLossFromNetInvestmentHedgesEuroDenominatedNotesIncludingPortionAttributableToNoncontrollingInterestMember 2019-12-31 0000874716 idxx:AccumulatedNetGainLossFromNetInvestmentHedgesCrossCurrencySwapsIncludingPortionAttributableToNoncontrollingInterestMember 2019-12-31 0000874716 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2019-12-31 0000874716 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2019-12-31 0000874716 idxx:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleIncludingPortionAttributableToNoncontrollingInterestMember 2020-01-01 2020-06-30 0000874716 idxx:AccumulatedNetGainLossFromCashFlowHedgesForeignCurrencyExchangeContractsIncludingPortionAttributableToNoncontrollingInterestMember 2020-01-01 2020-06-30 0000874716 idxx:AccumulatedNetGainLossFromNetInvestmentHedgesEuroDenominatedNotesIncludingPortionAttributableToNoncontrollingInterestMember 2020-01-01 2020-06-30 0000874716 idxx:AccumulatedNetGainLossFromNetInvestmentHedgesCrossCurrencySwapsIncludingPortionAttributableToNoncontrollingInterestMember 2020-01-01 2020-06-30 0000874716 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2020-01-01 2020-06-30 0000874716 idxx:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleIncludingPortionAttributableToNoncontrollingInterestMember 2020-06-30 0000874716 idxx:AccumulatedNetGainLossFromCashFlowHedgesForeignCurrencyExchangeContractsIncludingPortionAttributableToNoncontrollingInterestMember 2020-06-30 0000874716 idxx:AccumulatedNetGainLossFromNetInvestmentHedgesEuroDenominatedNotesIncludingPortionAttributableToNoncontrollingInterestMember 2020-06-30 0000874716 idxx:AccumulatedNetGainLossFromNetInvestmentHedgesCrossCurrencySwapsIncludingPortionAttributableToNoncontrollingInterestMember 2020-06-30 0000874716 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2020-06-30 0000874716 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2020-06-30 0000874716 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember idxx:AccumulatedNetGainLossFromCashFlowHedgesForeignCurrencyExchangeContractsIncludingPortionAttributableToNoncontrollingInterestMember 2021-04-01 2021-06-30 0000874716 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember idxx:AccumulatedNetGainLossFromCashFlowHedgesForeignCurrencyExchangeContractsIncludingPortionAttributableToNoncontrollingInterestMember 2020-04-01 2020-06-30 0000874716 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember idxx:AccumulatedNetGainLossFromCashFlowHedgesForeignCurrencyExchangeContractsIncludingPortionAttributableToNoncontrollingInterestMember 2021-01-01 2021-06-30 0000874716 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember idxx:AccumulatedNetGainLossFromCashFlowHedgesForeignCurrencyExchangeContractsIncludingPortionAttributableToNoncontrollingInterestMember 2020-01-01 2020-06-30 0000874716 us-gaap:StockCompensationPlanMember 2021-04-01 2021-06-30 0000874716 us-gaap:StockCompensationPlanMember 2020-04-01 2020-06-30 0000874716 us-gaap:StockCompensationPlanMember 2021-01-01 2021-06-30 0000874716 us-gaap:StockCompensationPlanMember 2020-01-01 2020-06-30 0000874716 us-gaap:EmployeeStockOptionMember 2021-04-01 2021-06-30 0000874716 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-06-30 0000874716 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0000874716 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0000874716 2020-09-30 0000874716 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-06-30 0000874716 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-06-30 0000874716 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-12-31 0000874716 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-12-31 0000874716 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-06-30 0000874716 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-06-30 0000874716 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-06-30 0000874716 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-06-30 0000874716 idxx:EquityMutualFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000874716 idxx:EquityMutualFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000874716 idxx:EquityMutualFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000874716 idxx:EquityMutualFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000874716 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000874716 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000874716 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000874716 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000874716 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000874716 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000874716 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000874716 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000874716 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember idxx:DeferredCompensationMember 2021-06-30 0000874716 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember idxx:DeferredCompensationMember 2021-06-30 0000874716 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember idxx:DeferredCompensationMember 2021-06-30 0000874716 us-gaap:FairValueMeasurementsRecurringMember idxx:DeferredCompensationMember 2021-06-30 0000874716 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember idxx:ContingentPaymentMember 2021-06-30 0000874716 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember idxx:ContingentPaymentMember 2021-06-30 0000874716 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember idxx:ContingentPaymentMember 2021-06-30 0000874716 us-gaap:FairValueMeasurementsRecurringMember idxx:ContingentPaymentMember 2021-06-30 0000874716 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-12-31 0000874716 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-12-31 0000874716 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-12-31 0000874716 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-12-31 0000874716 idxx:EquityMutualFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000874716 idxx:EquityMutualFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000874716 idxx:EquityMutualFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000874716 idxx:EquityMutualFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000874716 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000874716 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000874716 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000874716 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000874716 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000874716 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000874716 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000874716 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000874716 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember idxx:DeferredCompensationMember 2020-12-31 0000874716 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember idxx:DeferredCompensationMember 2020-12-31 0000874716 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember idxx:DeferredCompensationMember 2020-12-31 0000874716 us-gaap:FairValueMeasurementsRecurringMember idxx:DeferredCompensationMember 2020-12-31 0000874716 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2021-04-01 2021-06-30 0000874716 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2020-04-01 2020-06-30 0000874716 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2021-01-01 2021-06-30 0000874716 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2020-01-01 2020-06-30 iso4217:EUR 0000874716 idxx:SeriesCSeniorNoteMember 2015-06-30 0000874716 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-06-30 0000874716 us-gaap:CrossCurrencyInterestRateContractMember srt:ScenarioForecastMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 2023-06-30 0000874716 idxx:CrossCurrencyInterestRateContract1Member us-gaap:DesignatedAsHedgingInstrumentMember 2021-06-30 0000874716 srt:ScenarioForecastMember idxx:CrossCurrencyInterestRateContract1Member us-gaap:DesignatedAsHedgingInstrumentMember 2025-06-18 2025-06-18 0000874716 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:OtherCurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-06-30 0000874716 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:OtherCurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000874716 us-gaap:CashFlowHedgingMember us-gaap:OtherNoncurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-06-30 0000874716 us-gaap:CashFlowHedgingMember us-gaap:OtherNoncurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000874716 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:OtherNoncurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-06-30 0000874716 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:OtherNoncurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000874716 us-gaap:DesignatedAsHedgingInstrumentMember 2021-06-30 0000874716 us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000874716 us-gaap:ForeignExchangeContractMember us-gaap:AccruedLiabilitiesMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-06-30 0000874716 us-gaap:ForeignExchangeContractMember us-gaap:AccruedLiabilitiesMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000874716 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-06-30 0000874716 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000874716 us-gaap:ForeignExchangeContractMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-06-30 0000874716 us-gaap:ForeignExchangeContractMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000874716 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-06-30 0000874716 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000874716 us-gaap:LongTermDebtMember us-gaap:DesignatedAsHedgingInstrumentMember idxx:ForeignCurrencyBorrowingsDesignatedAsNetInvestmentHedgeOnBalanceSheetMember 2021-06-30 0000874716 us-gaap:LongTermDebtMember us-gaap:DesignatedAsHedgingInstrumentMember idxx:ForeignCurrencyBorrowingsDesignatedAsNetInvestmentHedgeOnBalanceSheetMember 2020-12-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2021
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______________ to _______________.
COMMISSION FILE NUMBER: 000-19271
IDEXX LABORATORIES, INC.
(Exact name of registrant as specified in its charter)

Delaware |  |  | 01-0393723
(State or other jurisdiction of incorporation or organization) |  |  | (IRS Employer Identification No.)
One IDEXX Drive | Westbrook | Maine | 04092
(Address of principal executive offices) |  |  | (ZIP Code)

207-556-0300
(Registrant’s telephone number, including area code)
Securities Registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock, $0.10 par value per share |  | IDXX |  | NASDAQ Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ý No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer | ☒ |  | Accelerated filer | ☐
Non-accelerated filer | ☐ |  | Smaller reporting company | ☐
|  |  | Emerging growth company | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. The number of shares outstanding of the registrant’s Common Stock, $0.10 par value per share, was 85,075,932, o n July 26, 2021.

GLOSSARY OF TERMS AND SELECTED ABBREVIATIONS
In order to aid the reader, we have included certain terms and abbreviations used throughout this Quarterly Report on Form 10-Q below:

Term/ Abbreviation | Definition
AOCI | Accumulated other comprehensive income or loss
CAG | Companion Animal Group, a reporting segment that provides veterinarians diagnostic products and services and information management solutions that enhance the health and well-being of pets.
Credit Facility | Our $1 billion unsecured revolving credit facility, also referred to as line of credit.
Clinical visits | The reason for the visit involves an interaction between a clinician and a pet, including wellness and non-wellness visit types.
FASB | U.S. Financial Accounting Standards Board
LPD | Livestock, Poultry and Dairy, a reporting segment that provides diagnostic products and services for livestock and poultry health and to ensure the quality and safety of milk and improve producer efficiency.
Non-wellness visits | Patient visits where the reason for the visit is sickness, procedure, or monitoring.
OPTI Medical | OPTI Medical Systems, Inc., a wholly-owned subsidiary of IDEXX Laboratories Inc., located in Roswell, Georgia. This business provides point-of-care and laboratory diagnostics (including electrolyte and blood gas analyzers and related consumable products) for the human medical diagnostics market, as well as COVID-19 testing products and services. The Roswell facility also manufactures electrolytes slides (instrument consumables) to run Catalyst One®, Catalyst Dx®, and blood gas analyzers and consumables for the veterinary market; also referred to as OPTI.
Organic revenue growth | A non-GAAP financial measure and represents the percentage change in revenue, as compared to the same period for the prior year, net of the effect of changes in foreign currency exchange rates, certain business acquisitions and divestitures. Organic revenue growth should be considered in addition to, and not as a replacement for or as a superior measure to, revenue growth reported in accordance with U.S. GAAP, and may not be comparable to similarly titled measures reported by other companies.
PCR | Polymerase chain reaction, a technique used to amplify small segments of DNA
R&D | Research and Development
Reported revenue growth | Represents the percentage change in revenue reported in accordance with U.S. GAAP, as compared to the same period in the prior year.
SaaS | Software-as-a-service
SEC | U.S. Securities and Exchange Commission
Senior Note Agreements | Note purchase agreements for the private placement of senior notes, referred to as senior notes or long-term debt.
U.S. GAAP | Accounting principles generally accepted in the United States of America
Water | Water, a reporting segment that provides water microbiology testing products.
Wellness visits | Patient visits where the reason for the visit is an annual exam, vaccination, or routine check-up.

IDEXX LABORATORIES, INC.
Quarterly Report on Form 10-Q
Table of Contents

Item No. |  | Page
| PART I—FINANCIAL INFORMATION |
Item 1. | Financial Statements (unaudited) |
| Condensed Consolidated Balance Sheets as of June 30, 2021 and December 31, 2020 | 3
| Condensed Consolidated Statements of Income for the Three and Six Months Ended June 30, 2021 and 2020 | 4
| Condensed Consolidated Statements of Comprehensive Income for the Three and Six Months Ended June 30, 2021 and 2020 | 5
| Condensed Consolidated Statements of Stockholders' Equity for the Three and Six Months Ended June 30, 2021 and 2020 | 6
| Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2021 and 2020 | 7
| Notes to Condensed Consolidated Financial Statements (Unaudited) | 8
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 30
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 51
Item 4. | Controls and Procedures | 53
| PART II—OTHER INFORMATION |
Item 1. | Legal Proceedings | 53
Item 1A. | Risk Factors | 53
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 54
Item 6. | Exhibits | 55
Signatures |  | 56

PART I— FINANCIAL INFORMATION
Item 1. Financial Statements.
IDEXX LABORATORIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except per share amounts)
(Unaudited)

| June 30, 2021 |  | December 31, 2020
ASSETS |  |  |
Current Assets: |  |  |
Cash and cash equivalents | $ | 232,134 |  |  | $ | 383,928 |
Accounts receivable, net | 382,308 |  |  | 331,429 |
Inventories | 241,392 |  |  | 209,873 |
Other current assets | 145,392 |  |  | 137,508 |
Total current assets | 1,001,226 |  |  | 1,062,738 |
Long-Term Assets: |  |  |
Property and equipment, net | 550,255 |  |  | 555,167 |
Operating lease right-of-use assets | 104,723 |  |  | 91,171 |
Goodwill | 353,842 |  |  | 243,347 |
Intangible assets, net | 96,757 |  |  | 52,543 |
Other long-term assets | 305,346 |  |  | 289,595 |
Total long-term assets | 1,410,923 |  |  | 1,231,823 |
TOTAL ASSETS | $ | 2,412,149 |  |  | $ | 2,294,561 |
LIABILITIES AND STOCKHOLDERS’ EQUITY |  |  |
Current Liabilities: |  |  |
Accounts payable | $ | 93,016 |  |  | $ | 74,558 |
Accrued liabilities | 392,681 |  |  | 415,648 |
Current portion of long-term debt | 124,982 |  |  | 49,988 |
Current portion of deferred revenue | 41,130 |  |  | 42,567 |
Total current liabilities | 651,809 |  |  | 582,761 |
Long-Term Liabilities: |  |  |
Deferred income tax liabilities | 15,469 |  |  | 11,707 |
Long-term debt, net of current portion | 780,079 |  |  | 858,492 |
Long-term deferred revenue, net of current portion | 43,196 |  |  | 46,163 |
Long-term operating lease liabilities | 88,330 |  |  | 77,039 |
Other long-term liabilities | 85,043 |  |  | 85,604 |
Total long-term liabilities | 1,012,117 |  |  | 1,079,005 |
Total liabilities | 1,663,926 |  |  | 1,661,766 |
Commitments and Contingencies (Note 15) |  |  |
Stockholders’ Equity: |  |  |
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued:106,748 shares in 2021 and 106,457 shares in 2020; Outstanding: 85,096 shares in 2021 and 85,449 shares in 2020 | 10,675 |  |  | 10,646 |
Additional paid-in capital | 1,339,413 |  |  | 1,294,849 |
Deferred stock units: Outstanding: 90 units in 2021 and 87 units in 2020 | 5,630 |  |  | 4,503 |
Retained earnings | 2,582,434 |  |  | 2,175,595 |
Accumulated other comprehensive loss | (48,391) |  |  | (53,615) |
Treasury stock, at cost: 21,653 shares in 2021 and 21,008 shares in 2020 | (3,142,301) |  |  | (2,799,890) |
Total IDEXX Laboratories, Inc. stockholders’ equity | 747,460 |  |  | 632,088 |
Noncontrolling interest | 763 |  |  | 707 |
Total stockholders’ equity | 748,223 |  |  | 632,795 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 2,412,149 |  |  | $ | 2,294,561 |
The accompanying notes are an integral part of these condensed consolidated financial statements.

3

IDEXX LABORATORIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share amounts)
(Unaudited)

| For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
Revenue: |  |  |  |  |  |  |
Product revenue | $ | 480,715 |  |  | $ | 366,058 |  |  | $ | 935,063 |  |  | $ | 730,831 |
Service revenue | 345,427 |  |  | 271,534 |  |  | 668,786 |  |  | 533,097 |
Total revenue | 826,142 |  |  | 637,592 |  |  | 1,603,849 |  |  | 1,263,928 |
Cost of Revenue: |  |  |  |  |  |  |
Cost of product revenue | 169,832 |  |  | 124,024 |  |  | 317,102 |  |  | 249,478 |
Cost of service revenue | 167,002 |  |  | 134,226 |  |  | 326,657 |  |  | 275,518 |
Total cost of revenue | 336,834 |  |  | 258,250 |  |  | 643,759 |  |  | 524,996 |
Gross profit | 489,308 |  |  | 379,342 |  |  | 960,090 |  |  | 738,932 |
Expenses: |  |  |  |  |  |  |
Sales and marketing | 119,032 |  |  | 94,181 |  |  | 233,843 |  |  | 210,324 |
General and administrative | 73,326 |  |  | 60,268 |  |  | 144,096 |  |  | 126,080 |
Research and development | 37,697 |  |  | 31,645 |  |  | 75,276 |  |  | 64,955 |
Income from operations | 259,253 |  |  | 193,248 |  |  | 506,875 |  |  | 337,573 |
Interest expense | (7,613) |  |  | (9,495) |  |  | (15,197) |  |  | (17,187) |
Interest income | 91 |  |  | 69 |  |  | 143 |  |  | 209 |
Income before provision for income taxes | 251,731 |  |  | 183,822 |  |  | 491,821 |  |  | 320,595 |
Provision for income taxes | 49,125 |  |  | 34,826 |  |  | 84,926 |  |  | 59,743 |
Net income | 202,606 |  |  | 148,996 |  |  | 406,895 |  |  | 260,852 |
Less: Net income attributable to noncontrolling interest | 24 |  |  | 56 |  |  | 56 |  |  | 85 |
Net income attributable to IDEXX Laboratories, Inc. stockholders | $ | 202,582 |  |  | $ | 148,940 |  |  | $ | 406,839 |  |  | $ | 260,767 |
Earnings per Share: |  |  |  |  |  |  |
Basic | $ | 2.37 |  |  | $ | 1.75 |  |  | $ | 4.76 |  |  | $ | 3.06 |
Diluted | $ | 2.34 |  |  | $ | 1.72 |  |  | $ | 4.69 |  |  | $ | 3.01 |
Weighted Average Shares Outstanding: |  |  |  |  |  |  |
Basic | 85,325 |  |  | 85,134 |  |  | 85,427 |  |  | 85,282 |
Diluted | 86,654 |  |  | 86,402 |  |  | 86,794 |  |  | 86,568 |
The accompanying notes are an integral part of these condensed consolidated financial statements. |  |  |  |  |  |  |

4

IDEXX LABORATORIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(in thousands)
(Unaudited)

| For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
Net income | $ | 202,606 |  |  | $ | 148,996 |  |  | $ | 406,895 |  |  | $ | 260,852 |
Other comprehensive income (loss), net of tax: |  |  |  |  |  |  |
Foreign currency translation adjustments | 12,087 |  |  | 7,006 |  |  | (7,246) |  |  | (15,200) |
Unrealized gain (loss) on Euro-denominated notes, net of tax expense (benefit) of $(313) and $837 in 2021 and $(532) and $(202) in 2020 | (994) |  |  | (1,689) |  |  | 2,654 |  |  | (642) |
Unrealized gain (loss) on investments, net of tax expense (benefit) of $2 and $48 in 2021 and $(93) and $(181) in 2020 | 7 |  |  | (295) |  |  | 154 |  |  | (574) |
Unrealized gain (loss) on derivative instruments: |  |  |  |  |  |  |
Unrealized gain (loss) on foreign currency exchange contracts, net of tax expense (benefit) of $(594) and $655 in 2021 and $(805) and $1,247 in 2020 | (1,224) |  |  | (3,888) |  |  | 3,191 |  |  | 5,538 |
Unrealized gain (loss) on cross currency swaps, net of tax expense (benefit) of $(349) and $694 in 2021 and $(283) and $586 in 2020 | (1,106) |  |  | (1,447) |  |  | 2,202 |  |  | 2,602 |
Reclassification adjustment for loss (gain) included in net income, net of tax benefit (expense) of $340 and $876 in 2021 and $(339) and $(579) in 2020 | 2,375 |  |  | (1,473) |  |  | 4,269 |  |  | (2,574) |
Unrealized gain (loss) on derivative instruments | 45 |  |  | (6,808) |  |  | 9,662 |  |  | 5,566 |
Other comprehensive gain (loss), net of tax | 11,145 |  |  | (1,786) |  |  | 5,224 |  |  | (10,850) |
Comprehensive income | 213,751 |  |  | 147,210 |  |  | 412,119 |  |  | 250,002 |
Less: Comprehensive income attributable to noncontrolling interest | 24 |  |  | 56 |  |  | 56 |  |  | 85 |
Comprehensive income attributable to IDEXX Laboratories, Inc. | $ | 213,727 |  |  | $ | 147,154 |  |  | $ | 412,063 |  |  | $ | 249,917 |
The accompanying notes are an integral part of these condensed consolidated financial statements. |  |  |  |  |  |  |

5

IDEXX LABORATORIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in thousands, except per share amounts)
(Unaudited)

| Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Number of Shares |  | $0.10 Par Value |  | Additional Paid-in Capital |  | Deferred Stock Units |  | Retained Earnings |  | Accumulated Other Comprehensive (Loss) Income |  | Treasury Stock |  | Noncontrolling Interest |  | Total Stockholders’ Equity
Balance December 31, 2020 | 106,457 |  |  | $ | 10,646 |  |  | $ | 1,294,849 |  |  | $ | 4,503 |  |  | $ | 2,175,595 |  |  | $ | (53,615) |  |  | $ | (2,799,890) |  |  | $ | 707 |  |  | $ | 632,795 |
Net income | — |  |  | — |  |  | — |  |  | — |  |  | 204,257 |  |  | — |  |  | — |  |  | 32 |  |  | 204,289 |
Other comprehensive loss, net | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (5,921) |  |  | — |  |  | — |  |  | (5,921) |
Repurchases of common stock, net | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (154,033) |  |  | — |  |  | (154,033) |
Common stock issued under stock plans | 219 |  |  | 22 |  |  | 17,408 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 17,430 |
Share-based compensation cost | — |  |  | — |  |  | 8,829 |  |  | 46 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 8,875 |
Balance March 31, 2021 | 106,676 |  |  | $ | 10,668 |  |  | $ | 1,321,086 |  |  | $ | 4,549 |  |  | $ | 2,379,852 |  |  | $ | (59,536) |  |  | $ | (2,953,923) |  |  | $ | 739 |  |  | $ | 703,435 |
Net income | — |  |  | — |  |  | — |  |  | — |  |  | 202,582 |  |  | — |  |  | — |  |  | 24 |  |  | 202,606 |
Other comprehensive income (loss), net | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 11,145 |  |  | — |  |  | — |  |  | 11,145 |
Repurchases of common stock | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (188,378) |  |  | — |  |  | (188,378) |
Common stock issued under stock plans, including excess tax benefit | 72 |  |  | 7 |  |  | 9,771 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 9,778 |
Deferred stock units activity | — |  |  | — |  |  | (1,035) |  |  | 1,035 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Share-based compensation cost | — |  |  | — |  |  | 9,591 |  |  | 46 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 9,637 |
Balance June 30, 2021 | 106,748 |  |  | $ | 10,675 |  |  | $ | 1,339,413 |  |  | $ | 5,630 |  |  | $ | 2,582,434 |  |  | $ | (48,391) |  |  | $ | (3,142,301) |  |  | $ | 763 |  |  | $ | 748,223 |

Balance December 31, 2019 | 105,711 |  |  | $ | 10,571 |  |  | $ | 1,213,517 |  |  | $ | 4,462 |  |  | $ | 1,595,648 |  |  | $ | (46,182) |  |  | $ | (2,600,543) |  |  | $ | 352 |  |  | $ | 177,825 |
Cumulative effect of accounting changes | — |  |  | — |  |  | — |  |  | — |  |  | (1,829) |  |  | — |  |  | — |  |  | — |  |  | (1,829) |
Net income | — |  |  | — |  |  | — |  |  | — |  |  | 111,827 |  |  | — |  |  | — |  |  | 29 |  |  | 111,856 |
Other comprehensive loss, net | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (9,064) |  |  | — |  |  | — |  |  | (9,064) |
Repurchases of common stock | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (187,767) |  |  | — |  |  | (187,767) |
Common stock issued under stock plans | 203 |  |  | 20 |  |  | 9,730 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 9,750 |
Share-based compensation cost | — |  |  | — |  |  | 7,238 |  |  | 46 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 7,284 |
Balance March 31, 2020 | 105,914 |  |  | $ | 10,591 |  |  | $ | 1,230,485 |  |  | $ | 4,508 |  |  | $ | 1,705,646 |  |  | $ | (55,246) |  |  | $ | (2,788,310) |  |  | $ | 381 |  |  | $ | 108,055 |
Net income | — |  |  | — |  |  | — |  |  | — |  |  | 148,940 |  |  | — |  |  | — |  |  | 56 |  |  | 148,996 |
Other comprehensive loss, net | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (1,786) |  |  | — |  |  | — |  |  | (1,786) |
Issuance of common stock | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 258 |  |  | — |  |  | 258 |
Common stock issued under stock plans, including excess tax benefit | 117 |  |  | 12 |  |  | 10,068 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 10,080 |
Deferred stock units activity | — |  |  | — |  |  | (894) |  |  | 894 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Share-based compensation cost | — |  |  | — |  |  | 7,797 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 7,797 |
Balance June 30, 2020 | 106,031 |  |  | $ | 10,603 |  |  | $ | 1,247,456 |  |  | $ | 5,402 |  |  | $ | 1,854,586 |  |  | $ | (57,032) |  |  | $ | (2,788,052) |  |  | $ | 437 |  |  | $ | 273,400 |
The accompanying notes are an integral part of these condensed consolidated financial statements.

6

IDEXX LABORATORIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(Unaudited)

| For the Six Months Ended June 30,
| 2021 |  | 2020
Cash Flows from Operating Activities: |  |  |
Net income | $ | 406,895 |  |  | $ | 260,852 |
Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
Depreciation and amortization | 50,434 |  |  | 46,786 |
Impairment charge | 3,795 |  |  | — |
Provision for credit losses | 768 |  |  | 5,352 |
Deferred income taxes | 4,193 |  |  | 2,658 |
Share-based compensation expense | 18,512 |  |  | 15,081 |
Other | 1,300 |  |  | 699 |
Changes in assets and liabilities: |  |  |
Accounts receivable | (50,721) |  |  | (57,277) |
Inventories | (20,412) |  |  | (29,254) |
Other assets and liabilities | (55,162) |  |  | 4,540 |
Accounts payable | 3,812 |  |  | (6,729) |
Deferred revenue | (5,037) |  |  | (6,695) |
Net cash provided by operating activities | 358,377 |  |  | 236,013 |
Cash Flows from Investing Activities: |  |  |
Purchases of property and equipment | (42,744) |  |  | (73,558) |
Acquisition of intangible assets and equity investment | — |  |  | (668) |
Acquisitions of a business, net of cash acquired | (156,506) |  |  | — |
Net cash used by investing activities | (199,250) |  |  | (74,226) |
Cash Flows from Financing Activities: |  |  |
Repayments on revolving credit facilities, net | — |  |  | (167,692) |
Issuance of senior debt | — |  |  | 200,000 |
Debt issuance costs | — |  |  | (4,988) |
Payments of acquisition-related contingent considerations and holdbacks | (1,500) |  |  | (1,080) |
Repurchases of common stock, net | (320,787) |  |  | (182,815) |
Proceeds from exercises of stock options and employee stock purchase plans | 27,371 |  |  | 20,613 |
Shares withheld for statutory tax withholding on restricted stock | (14,952) |  |  | (8,668) |
Net cash used by financing activities | (309,868) |  |  | (144,630) |
Net effect of changes in exchange rates on cash | (1,053) |  |  | (2,190) |
Net (decrease) increase in cash and cash equivalents | (151,794) |  |  | 14,967 |
Cash and cash equivalents at beginning of period | 383,928 |  |  | 90,326 |
Cash and cash equivalents at end of period | $ | 232,134 |  |  | $ | 105,293 |
Supplemental Cash Flow Information: |  |  |
Cash paid for income taxes | $ | 81,923 |  |  | $ | 29,983 |
Unpaid property and equipment, reflected in accounts payable and accrued liabilities | $ | 9,676 |  |  | $ | 12,670 |
The accompanying notes are an integral part of these condensed consolidated financial statements.

7

IDEXX LABORATORIES, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 1. BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION
The accompanying unaudited condensed consolidated financial statements of IDEXX Laboratories, Inc. and its subsidiaries have been prepared in accordance with U.S. GAAP for interim financial information and with the requirements of Regulation S-X, Rule 10-01 for financial statements required to be filed as a part of this Quarterly Report on Form 10-Q. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “IDEXX,” the “Company,” “we,” “our,” or “us” refer to IDEXX Laboratories, Inc. and its subsidiaries.
The accompanying unaudited condensed consolidated financial statements include the accounts of IDEXX Laboratories, Inc. and our wholly-owned and majority-owned subsidiaries. We do not have any variable interest entities for which we are the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.
The accompanying unaudited condensed consolidated financial statements reflect, in the opinion of our management, all adjustments necessary for a fair statement of our financial position and results of operations. All such adjustments are of a recurring nature. The consolidated balance sheet data at December 31, 2020, was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for the three and six months ended June 30, 2021, are not necessarily indicative of the results to be expected for the full year or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with this Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, and our Annual Report on Form 10-K for the year ended December 31, 2020, (the “2020 Annual Report”) filed with the SEC.
The preparation of our condensed consolidated financial statements requires us to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues, and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments, and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity, and the amount of revenues and expenses.
We have included certain terms and abbreviations used throughout this Quarterly Report on Form 10-Q in the “Glossary of Terms and Selected Abbreviations.”
NOTE 2. ACCOUNTING POLICIES
Significant Accounting Policies
The significant accounting policies used in preparation of these unaudited condensed consolidated financial statements as of and for the three and six months ended June 30, 2021, are consistent with those discussed in Note 2. Summary of Significant Accounting Policies to the consolidated financial statements in our 2020 Annual Report, except as noted below.
New Accounting Pronouncements Adopted
Effective January 1, 2021, we adopted ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” The new guidance is intended to simplify the accounting for income taxes by removing certain exceptions and by updating accounting requirements around goodwill recognized for tax purposes and the allocation of current and deferred tax expense among legal entities, among other minor changes. The adoption of ASU 2019-12 did not have a material impact on our consolidated financial statements.
New Accounting Pronouncements Not Yet Adopted
In July 2021, the FASB issued ASU 2021-05, “Leases (Topic 842); Lessors - Certain Leases with Variable Lease Payments.” ASU 2021-05 requires a lessor to classify a lease with variable payments that do not depend on an index or rate as an operating lease if another lease classification (i.e., sales-type or direct financing) would result in recognition of a day-one loss. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, and earlier adoption is permitted. We have elected to adopt this
8

standard as of July 1, 2021, on a prospective basis. We do not expect the adoption of ASU 2021-05 to have a material impact on our consolidated financial statements.
In March 2020, the FASB issued ASU 2020-04, "Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” ASU 2020-04 is intended to provide optional expedients and exceptions to the U.S. GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens related to the discontinuation of the London Interbank Offered Rate (“LIBOR”) or by another reference rate expected to be discontinued. The relief offered by this guidance, if adopted, is available to companies for the period March 12, 2020 through December 31, 2022. We do not expect the discontinuation of LIBOR to have a material impact on our consolidated financial statements.
NOTE 3. REVENUE RECOGNITION
Our revenue is recognized when, or as, performance obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to a customer. We exclude sales, use, value-added, and other taxes we collect on behalf of third parties from revenue. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or services to a customer. To accurately present the consideration received in exchange for promised products or services, we apply the five-step model outlined below:
1.Identification of a contract or agreement with a customer
2.Identification of our performance obligations in the contract or agreement
3.Determination of the transaction price
4.Allocation of the transaction price to the performance obligations
5.Recognition of revenue when, or as, we satisfy a performance obligation
We enter into contracts that can include various combinations of products and services, which are generally capable of being distinct and accounted for as separate performance obligations. The timing of revenue recognition, billings, and cash collections results in accounts receivable, contract assets and lease receivables as a result of revenue recognized in advance of billings (included within other assets), and contract liabilities or deferred revenue as a result of receiving consideration in advance of revenue recognition within our unaudited condensed consolidated balance sheet. Our general payment terms range from 30 to 60 days, with exceptions in certain geographies. Below is a listing of our major categories of revenue for our products and services:
Diagnostic Products and Accessories. Diagnostic products and accessories revenues, including IDEXX VetLab® consumables and accessories, rapid assay, LPD, Water, and OPTI testing products, are predominantly recognized and invoiced at the time of shipment, which is when the customer obtains control of the product based on legal title transfer and we have the right to payment. Shipping costs reimbursed by the customer are included in revenue and cost of sales. As a practical expedient, we do not account for shipping activities as a separate performance obligation.
Reference Laboratory Diagnostic and Consulting Services. Reference laboratory revenues are recognized and invoiced when the laboratory diagnostic service is performed.
Instruments, Software and Systems. CAG Diagnostics capital instruments, veterinary software and diagnostic imaging systems revenues are recognized and invoiced when the customer obtains control of the products based on legal title transfer and we have the right to payment, which generally occurs at the time of installation and customer acceptance. Our instruments, software, and systems are often included in one of our significant customer programs, as further described below. For veterinary software systems that include multiple performance obligations, such as perpetual software licenses and computer hardware, we allocate revenue to each performance obligation based on estimates of the price that we would charge the customer for each promised product or service if it were sold on a standalone basis.
Lease Revenue. Revenues from instrument rental agreements and reagent rental programs are recognized either as operating leases on a ratable basis over the term of the agreement or as sales-type leases at the time of installation and customer acceptance. Customers typically pay for the right to use instruments under rental agreements in equal monthly amounts over the term of the rental agreement. Our reagent rental programs provide our customers the right to use our instruments upon entering into agreements to purchase specified amounts of consumables, which are considered embedded leases. For some agreements, the customers are provided with the right to purchase the instrument at the end of the lease term. Lease revenues from these agreements are presented in product revenue on our unaudited condensed consolidated income statement. Lease revenue was approximately $4.7 million and $9.5 million for the three and six months ended June 30, 2021, respectively, as compared to $3.5 million and $7.7 million for the three and six months ended June 30, 2020, respectively, including both operating leases
9

and sales-type leases under ASC 842, Leases, for leases entered into after January 1, 2019, and ASC 840, Leases, for leases entered into prior to 2019. See below for revenue recognition under our reagent rental programs.
Extended Warranties and Post-Contract Support. CAG Diagnostics capital instruments and diagnostic imaging systems extended warranties typically provide customers with continued coverage for a period of one to five years beyond the first-year standard warranty. Customers can either pay in full for the extended warranty at the time of instrument or system purchase or can be billed on a quarterly basis over the term of the contract. We recognize revenue associated with extended warranties over time on a ratable basis using a time elapsed measure of performance over the contract term, which approximates the expected timing in which applicable services are performed.
Veterinary software post-contract support provides customers with access to technical support when and as needed through access to call centers and online customer assistance. Post-contract support contracts typically have a term of 12 months and customers are billed for post-contract support in equal quarterly amounts over the term. We recognize revenue for post-contract support services over time on a ratable basis using a time elapsed measure of performance over the contract term, which approximates the expected timing in which applicable services are performed.
On December 31, 2020, our deferred revenue related to extended warranties and post-contract support was $35.1 million, of which approximately $3.1 million and $18.0 million was recognized during the three and six months ended June 30, 2021, respectively. Furthermore, as a result of new agreements, our deferred revenue related to extended warranties and post-contract support w as $32.2 million at June 30, 2021. We do not disclose information about remaining performance obligations that are part of contracts with an original expected duration of one year or less and do not adjust for the effect of the financing components when the period between customer payment and revenue recognition is one year or less. Deferred revenue related to extended warranties and post-contract support with an original duration of more than one year was $18.5 million at June 30, 2021, of which approximately 27%, 38%, 21%, 9%, and 5% are expected to be recognized during the remainder of 2021, the full years 2022, 2023, 2024, and thereafter, respectively. Additio nally, we have determined these agreements do not include a significant financing component.
SaaS Subscriptions. We offer a variety of veterinary software and diagnostic imaging SaaS subscriptions including IDEXX Neo®, Animana®, Pet Health Network® Pro, Petly® Plans, Web PACS, rVetLink®, Smart Flow™, and ezyVet®. We recognize revenue for our SaaS subscriptions over time on a ratable basis over the contract term, beginning on the date our service is made available to the customer. Our subscription contracts vary in term from monthly to two years. Customers typically pay for our subscription contracts in equal monthly amounts over the term of the agreement. Deferred revenue related to our SaaS subscriptions is not material.
Contracts with Multiple Performance Obligations. We enter into contracts where customers purchase a combination of IDEXX products and services. Determining whether products and services are considered distinct performance obligations that should be accounted for separately requires significant judgment. We determine the transaction price for a contract based on the consideration we expect to receive in exchange for the transferred goods or services. To the extent the transaction price includes variable consideration, such as volume rebates or expected price adjustments, we apply judgment in constraining the estimated variable consideration due to factors that may cause reversal of revenue recognized. We evaluate constraints based on our historical and projected experience with similar customer contracts.
We allocate revenue to each performance obligation in proportion to the relative standalone selling prices and recognize revenue when transfer of the related goods or services has occurred for each obligation. We utilize the observable standalone selling price when available, which represents the price charged for the performance obligation when sold separately. When standalone selling prices for our products or services are not directly observable, we determine the standalone selling prices using relevant information available and apply suitable estimation methods including, but not limited to, the cost plus a margin approach. We recognize revenue as each performance obligation is satisfied, either at a point in time or over time, as described in the revenue categories above. We do not disclose information about remaining performance obligations that are part of contracts with an original expected duration of one year or less.
10

The following customer programs represent our most significant customer contracts which contain multiple performance obligations:
Customer Commitment Programs. We offer customer incentives upon entering into multi-year agreements to purchase annual minimum amounts of products and services.
Up-Front Customer Loyalty Programs. Our up-front loyalty programs provide customers with incentives in the form of cash payments or IDEXX Points upon entering into multi-year agreements to purchase annual minimum amounts of future products or services. If a customer breaches its agreement, they are required to refund all or a portion of the up-front cash or IDEXX Points, or make other repayments, remedial actions, or both. Up-front incentives to customers in the form of cash or IDEXX Points are not made in exchange for distinct goods or services and are capitalized as customer acquisition costs within other current and long-term assets, which are subsequently recognized as a reduction to revenue over the term of the customer agreement. If these up-front incentives are subsequently utilized to purchase instruments, we allocate total consideration, including future committed purchases less up-front incentives and estimates of expected price adjustments, based on relative standalone selling prices to identified performance obligations and recognize instrument revenue and cost at the time of installation and customer acceptance. To the extent invoiced instrument revenue exceeds recognized instrument revenue, we record deferred revenue as a contract liability, which is subsequently recognized upon the purchase of future products and services. We have determined these agreements do not include a significant financing component. Differences between estimated and actual customer purchases may impact the amount and timing of revenue recognition.
On December 31, 2020, our capitalized customer acquisition costs were $148.1 million, of which approximately $11.1 million and $22.6 million was recognized as a reduction of revenue during the three and six months ended June 30, 2021, respectively. Furthermore, as a result of new up-front customer loyalty payments, net of subsequent recognition, our capitalized customer acquisition costs w er e $155.3 million at June 30, 2021. We monitor customer purchases over the term of their agreement to assess the realizability of our capitalized customer acquisition costs and review estimates of variable consideration. Impairments, revenue adjustments that relate to performance obligations satisfied in prior periods, and contract modifications during the three and six months ended June 30, 2021, were not material.
Volume Commitment Programs. Our volume commitment programs, such as our IDEXX 360 program, provide customers with a free or discounted instrument or system upon entering into multi-year agreements to purchase annual minimum amounts of products and services. We allocate total consideration, including future committed purchases and expected price adjustments, based on relative standalone selling prices to identified performance obligations and recognize instrument revenue and cost at the time of installation and customer acceptance in advance of billing the customer, which is also when the customer obtains control of the instrument based on legal title transfer. Our right to future consideration related to instrument revenue is recorded as a contract asset within other current and long-term assets. The contract asset is transferred to accounts receivable when customers are billed for future products and services over the term of the contract. We have determined these agreements do not include a significant financing component. Differences between estimated and actual customer purchases may impact the amount and timing of revenue recognition.
On December 31, 2020, our volume commitment contract assets were $115.5 million, of which approximately $6.7 million and $13.6 million was reclassified to accounts receivable when customers were billed for related products and services during the three and six months ended June 30, 2021, respectively. Furthermore, as a result of new placements under volume commitment programs, net of subsequent amounts reclassified to accounts receivable, and allowances established for credit losses, our contract assets we re $134.7 million a t June 30, 2021. We monitor customer purchases over the term of their agreement to assess the realizability of our contract assets and review estimates of variable consideration. Impairments, revenue adjustments that relate to performance obligations satisfied in prior periods, and contract modifications during the three and six months ended June 30, 2021, were not material.
For our up-front customer loyalty and volume commitment programs, we estimate future revenues related to multi-year agreements to be approximately $2.5 billion, of which approximately 13%, 25%, 23%, 18%, and 21% are expected to be recognized during the remainder of 2021, the full years 2022, 2023, 2024, and thereafter, respectively. These future revenues relate to performance obligations not yet satisfied, for which customers have committed to
11

purchase goods and services, net of the expected revenue reductions from customer acquisition costs and expected price adjustments, and as a result, are lower than stated contractual commitments by our customers.
Instrument Rebate Programs. Our instrument rebate programs require an instrument purchase and provide customers the opportunity to earn future rebates based on the volume of products and services they purchase over the term of the program. We account for the customer’s right to earn rebates on future purchases as a separate performance obligation and determine the standalone selling price based on an estimate of rebates the customer will earn over the term of the program. Total consideration allocated to identified performance obligations is limited to goods and services that the customer is presently obligated to purchase and does not include estimates of future purchases that are optional. We allocate total consideration to identified performance obligations, including the customer’s right to earn rebates on future purchases, which is deferred and recognized upon the purchase of future products and services, offsetting future rebates as they are earned.
On December 31, 2020, our deferred revenue related to instrument rebate programs was $39.3 million, of which approximately $3.6 million and $7.5 million was recognized when customers purchased eligible products and services and earned rebates during the three and six months ended June 30, 2021, respectively. Furthermore, as a result of new instrument purchases under rebate progr ams, net of subsequent recognition, our deferred revenue was $35.4 million at June 30, 2021, of which approximately 21%, 31%, 21%, 13%, and 14% are expected to be recognized during the remainder of 2021, the full years 2022, 2023, 2024, and thereafter, respectively.
Reagent Rental Programs. Our reagent rental programs provide our customers the right to use our instruments upon entering into multi-year agreements to purchase annual minimum amounts of consumables. These types of agreements include an embedded lease for the right to use our instrument, and we determine the amount of lease revenue allocated to the instrument based on relative standalone selling prices. We evaluate the terms of these embedded leases to determine classification as either a sales-type lease or an operating lease.
Sales-type Reagent Rental Programs. Our reagent rental programs that effectively transfer control of instruments to our customers are classified as sales-type leases, and we recognize instrument revenue and cost in advance of billing the customer, at the time of installation and customer acceptance. Our right to future consideration related to instrument revenue is recorded as a lease receivable within other current and long-term assets, and is transferred to accounts receivable when customers are billed for future products and services over the term of the contract. On December 31, 2020, our lease receivable assets were $11.1 million, of which approxim ately $0.6 million and $1.1 million was reclassified to accounts receivable when customers were billed for related products and services during the three and six months ended June 30, 2021, respectively. Furthermore, as a result of new placements under sales-type reagent rental programs, net of subsequent amounts reclassified to accounts receivable, and allowances established for credit losses, our lease receivable ass ets we re $13.0 million a t June 30, 2021. The impacts of discounting and unearned income at June 30, 2021, were not material. Profit and loss recognized at the commencement date and interest income during the three and six months ended June 30, 2021, were not material. We monitor customer purchases over the term of their agreement to assess the realizability of our lease receivable assets. Impairments during the three and six months ended June 30, 2021 were not material.
Operating-type Reagent Rental Programs. Our reagent rental programs that do not effectively transfer control of instruments to our customers are classified as operating leases, and we recognize instrument revenue and costs ratably over the term of the agreement. The cost of the instrument is capitalized within property and equipment. During the three and six months ended June 30, 2021, we transferred instrume nts of $3.3 million and $5.8 million, respectively, as compared to $1.7 million and $4.1 million for the three and six months ended June 30, 2020, from inventory to property and equipment. We had impairments of $3.8 million for both the three and six months ended June 30, 2021, associated with a write-down of rental assets in certain regions.
We estimate future revenue to be recognized related to our reagent rental programs of approximately $38.4 million, of which approximately 18%, 30%, 23%, 16%, and 13% are expected to be recognized during the remainder of 2021, the full years 2022, 2023, 2024, and thereafter, respectively. These future revenues relate to performance obligations not yet satisfied for which customers have committed to future purchases, net of any expected price adjustments, and as a result, may be lower than stated contractual commitments by our customers.
Other Customer Incentive Programs. Certain agreements with customers include discounts or rebates on the sale of products and services applied retrospectively, such as volume rebates achieved by purchasing a specified
12

purchase threshold of goods and services. We account for these discounts as variable consideration and estimate the likelihood of a customer meeting the threshold in order to determine the transaction price using the most predictive approach. We typically use the most-likely-amount method for incentives that are offered to individual customers and the expected-value method for programs that are offered to a broad group of customers. Revenue adjustments that relate to performance obligations satisfied in prior periods during the three and six months ended June 30, 2021, were not material. Refund obligations related to customer incentive programs are recorded in accrued liabilities for the actual issuance of incentives, incentives earned but not yet issued and estimates of incentives to be earned in the future.
Program Combinations. At times, we combine elements of our significant customer programs within a single customer contract. We separate each significant program element and include the contract assets, customer acquisition costs, deferred revenues and estimated future revenues within the most relevant program disclosures above. Each customer contract is presented as a net contract asset or net contract liability on our unaudited condensed consolidated balance sheet.
IDEXX Points. IDEXX Points may be applied to trade receivables due to us, converted to cash, or applied against the purchase price of IDEXX products and services. We consider IDEXX Points equivalent to cash. IDEXX Points that have not yet been used by customers are included in accrued liabilities until utilized or expired. Breakage is not material because customers can apply IDEXX Points to trade receivables at any time.
Accounts Receivable. We recognize revenue when it is probable that we will collect substantially all of the consideration to which we will be entitled, based on the customer’s intent and ability to pay the promised consideration. We apply judgment in determining the customer’s ability and intention to pay, which is based on a variety of factors including the customer’s historical payment experience or, in the case of a new customer, published credit and financial information pertaining to the customer. We have no significant customers that accounted for greater than 10% of our consolidated revenues, and we have no concentration of credit risk as of June 30, 2021.
Disaggregated Revenues. We present disaggregated revenue for our CAG segment based on major product and service categories. Our Water segment is comprised of a single major product category. Although our LPD segment does not meet the quantitative thresholds to be reported as a separate segment, we believe it is important to disaggregate these revenues as a major product and service category within our Other reportable segment given its distinct markets, and therefore we have elected to report LPD as a reportable segment.
The following table presents disaggregated revenue by major product and service categories:

(in thousands) | For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
CAG segment revenue: |  |  |  |  |  |  |
CAG Diagnostics recurring revenue: | $ | 661,300 |  |  | $ | 510,254 |  |  | $ | 1,278,580 |  |  | $ | 998,179 |
IDEXX VetLab consumables | 256,352 |  |  | 196,061 |  |  | 502,444 |  |  | 384,774 |
Rapid assay products | 83,887 |  |  | 64,658 |  |  | 153,498 |  |  | 122,088 |
Reference laboratory diagnostic and consulting services | 293,675 |  |  | 228,816 |  |  | 569,456 |  |  | 449,077 |
CAG Diagnostics services and accessories | 27,386 |  |  | 20,719 |  |  | 53,182 |  |  | 42,240 |
CAG Diagnostics capital - instruments | 35,054 |  |  | 18,871 |  |  | 66,244 |  |  | 42,704 |
Veterinary software, services and diagnostic imaging systems | 49,241 |  |  | 36,975 |  |  | 93,538 |  |  | 77,213 |
CAG segment revenue | 745,595 |  |  | 566,100 |  |  | 1,438,362 |  |  | 1,118,096 |
Water segment revenue | 37,191 |  |  | 28,116 |  |  | 71,231 |  |  | 62,265 |
LPD segment revenue | 33,524 |  |  | 32,244 |  |  | 72,794 |  |  | 66,398 |
Other segment revenue | 9,832 |  |  | 11,132 |  |  | 21,462 |  |  | 17,169 |
Total revenue | $ | 826,142 |  |  | $ | 637,592 |  |  | $ | 1,603,849 |  |  | $ | 1,263,928 |

13

Revenue by principal geographic area, based on customers’ domiciles, was as follows:

(in thousands) | For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
United States | $ | 515,238 |  |  | $ | 405,998 |  |  | $ | 987,876 |  |  | $ | 802,781 |
Europe, the Middle East and Africa | 171,553 |  |  | 123,969 |  |  | 342,803 |  |  | 253,735 |
Asia Pacific Region | 83,624 |  |  | 71,750 |  |  | 168,406 |  |  | 135,262 |
Canada | 39,337 |  |  | 25,357 |  |  | 72,795 |  |  | 49,604 |
Latin America | 16,390 |  |  | 10,518 |  |  | 31,969 |  |  | 22,546 |
Total revenue | $ | 826,142 |  |  | $ | 637,592 |  |  | $ | 1,603,849 |  |  | $ | 1,263,928 |

Costs to Obtain a Contract. We capitalize sales commissions and the related fringe benefits earned by our sales force when considered incremental and recoverable costs of obtaining a contract. Our contracts include performance obligations related to various goods and services, some of which are satisfied at a point in time and others over time. Commission costs related to performance obligations satisfied at a point in time are expensed at the time of sale, which is when revenue is recognized. Commission costs related to long-term service contracts and performance obligations satisfied over time, including extended warranties and SaaS subscriptions, are deferred and recognized on a systematic basis that is consistent with the transfer of the goods or services to which the asset relates. We apply judgment in estimating the amortization period, which ranges from 3 to 7 years, by taking into consideration our customer contract terms, history of renewals, expected length of customer relationship, as well as the useful life of the underlying technology and products. Amortization expense is included in sales and marketing expenses in the accompanying unaudited condensed consolidated statements of income. Deferred commission costs are periodically reviewed for impairment.
On December 31, 2020, our deferred commission costs, included within other assets, were $17.5 million, of which approximately $1.5 million and $3.0 million of co m mission expense was recognized during the three and six months ended June 30, 2021, respectively. Furthermore, as a result of commissions related to new extended warranties and SaaS subscriptions, net of subsequent recognition, our deferred commission costs were $18.4 million at June 30, 2021. Impairments of deferred commission costs, during the three and six months ended June 30, 2021, were not material.
14

NOTE 4. ACQUISITIONS
We believe that our acquisitions of businesses and other assets enhance our existing businesses by either expanding our geographic range and customer base or expanding our existing product lines. From time to time we may acquire small reference labs or radiology practices that we account for as either asset purchases or business combinations.
During the second quarter of 2021, we acquired the assets of the ezyVet cloud-based veterinary software businesses and the shares of ezyVet US, Inc., as well as the VetRadar business assets, for approximately $157.2 million, including an estimated contingent payment of $5 million. The acquired assets include the ezyVet cloud-native practice management system software and the VetRadar cloud-based workflow management software. The acquisition expands our cloud-based software offerings to support our customers with technology solutions that raise the standards of care for patients, improve practice efficiency, and enable more effective communication with pet owners. We estimate the preliminary fair value of assets acquired to be as follows: approximately $32.0 million in customer-related intangibles with a weighted average life of 10 years, approximately $8.4 million in technology-related intangibles with a weighted average life of 6 years, approximately $2.4 million in trademarks with a weighted average life of 14 years, approximately $1.8 million in non-compete agreements with a weighted average life of 5 years, approximately $109.4 million in goodwill, r epresenting synergies within our broader CAG portfolio, and approximately $3.2 million in net tangible assets. We have not completed our allocation of goodwill to reporting units within our CAG segment. The purchase price allocation is subject to revision as additional information becomes available regarding working capital adjustments, tax-related matters, contingencies, and certain assets and liabilities. Goodwill related to this acquisition is expected to be deductible for tax purposes. Pro forma information has not been presented for this acquisition because such information is not material to the financial statements. The results of operations have been included in our CAG segment since the acquisition date. The acquisition expenses were approximately $1.8 million.
During the first quarter of 2021, we acquired the shares of a reference laboratory located in Switzerland for approximately $5.5 million in cash, including holdback and contingent payments of approximately $1.1 million. This acquisition expands our international reference laboratory presence and was accounted for as a business combination. The fair value of the assets acquired consists of approximately $4.3 million in intangible assets, primarily for customer relationships, which will be amortized over 9 years, approximately $1.8 million for goodwill, representing synergies within our broader CAG portfolio, and approximately $0.6 million of liabilities, including deferred taxes associated with the acquired intangible assets. Goodwill related to this acquisition is not deductible for tax purposes. Pro forma information has not been presented for this acquisition because such information is not material to the financial statements. The results of operations have been included in our CAG segment since the acquisition date. The acquisition expenses were not material.
NOTE 5. SHARE-BASED COMPENSATION
The fair value of options, restricted stock units, deferred stock units, and employee stock purchase rights awarded during the three and six months ended June 30, 2021, totaled $4.0 million and $48.3 million, respectively, as compared to $2.3 million and $38.6 million for the three and six months ended June 30, 2020, respectively. The total unrecognized compensation expense, net of estimated forfeitures, for unvested share-based compensation awards outstanding at June 30, 2021, was $80.9 million, which will be recognized over a weighted average period of approximately 1.8 years. During the three and six months ended June 30, 2021, we recognized expenses of $9.6 million and $18.5 million, respectively, as compared to $7.8 million and $15.1 million for the three and six months ended June 30, 2020, respectively, related to share-based compensation.
We determine the assumptions used in the valuation of option awards as of the date of grant. Differences in the expected stock price volatility, expected term, or risk-free interest rate may necessitate distinct valuation assumptions at each grant date. As such, we may use different assumptions for options granted throughout the year. Option awards are granted with an exercise price equal to or greater than the closing market price of our common stock at the date of grant. We have never paid any cash dividends on our common stock, and we have no intention to pay such a dividend at this time; therefore, we assume that no dividends will be paid over the expected terms of option awards.
15

The weighted averages of the valuation assumptions used to determine the fair value of each option award on the date of grant and the weighted average estimated fair values were as follows:

| For the Six Months Ended June 30,
| 2021 |  | 2020
Share price at grant | $ | 542.57 |  |  | $ | 288.49 |
Share price at exercise | $ | 546.43 |  |  | $ | 288.49 |
Expected stock price volatility | 31 | % |  | 27 | %
Expected term, in years | 6.2 |  | 6.0
Risk-free interest rate | 0.7 | % |  | 1.4 | %
Weighted average fair value of options granted | $ | 167.94 |  |  | $ | 84.09 |

NOTE 6. CREDIT LOSSES
We are exposed to credit losses primarily through our sales of products and services to our customers. We maintain allowances for credit losses for potentially uncollectible receivables. We base our estimates on a detailed analysis of specific customer situations and a percentage of our accounts receivable by aging category. Historical credit loss experience provides the basis for the estimation of expected credit losses. Adjustments to historical loss information are made for differences in current economic conditions.
Additional allowances may be required if either the financial condition of our customers were to deteriorate, or a strengthening U.S. dollar impacts the ability of foreign customers to make payments to us on their U.S. dollar-denominated purchases. We monitor our ongoing credit exposure through active review of counterparty balances against contract terms and due dates. Our activities include timely account reconciliations, dispute resolution and payment confirmations. We may employ collection agencies and legal counsel to pursue recovery of defaulted receivables.
Account balances are charged off against the allowance when we believe it is probable the receivable will not be recovered. We may require collateralized asset support or a prepayment to mitigate credit risk. We do not have any off-balance sheet credit exposure related to our customers.
Accounts Receivable
The allowance for credit losses associated with accounts receiva bl e was $6.4 million and $6.8 million at June 30, 2021 and December 31, 2020, respectively. Accounts receivable reflected on the balance sheet is net of this reserve. Based on an aging analysis, at June 30, 2021, approximately 92% of our accounts receivable had not yet reached the invoice due date and approximately 8% was considered past due, of which approximately 1% was greater than 60 days past due. At December 31, 2020, approximately 88% of our accounts receivable had not yet reached the invoice due date and approximately 12% was considered past due, of which approximately 1.5% was greater than 60 days past due.
Contract assets and lease receivables
The allowance for credit losses associated with the contract assets and lease receivables was $4.0 million and $3.7 million at June 30, 2021 and December 31, 2020, respectively. The assets reflected on the balance sheet are net of these reserves. Historically, we have experienced low credit loss rates on our customer commitment programs and lease receivables. We apply judgment in determining the customer’s ability and intention to pay, which is based on a variety of factors including the customer’s historical payment experience or, in the case of a new customer, published credit and financial information pertaining to the customer.
16

NOTE 7. INVENTORIES
Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The components of inventories were as follows:

(in thousands) | June 30, 2021 |  | December 31, 2020
Raw materials | $ | 59,115 |  |  | $ | 45,986 |
Work-in-process | 25,103 |  |  | 20,374 |
Finished goods | 157,174 |  |  | 143,513 |
Inventories | $ | 241,392 |  |  | $ | 209,873 |

NOTE 8. LEASES
Maturities of operating lease liabilities were as follows:

(in thousands, except lease term and discount rate) | June 30, 2021
2021 (remainder of year) | $ | 9,945 |
2022 | 23,213 |
2023 | 18,917 |
2024 | 13,962 |
2025 | 10,697 |
Thereafter | 47,114 |
Total lease payments | 123,848 |
Less imputed interest | (16,283) |
Total | $ | 107,565 |

Total minimum future lease payments for leases that have not commenced as of June 30, 2021, are immaterial.
Supplemental cash flow information for leases was as follows:

(in thousands) |  | For the Six Months Ended June 30, 2021 |  | For the Six Months Ended June 30, 2020
Cash paid for amounts included in the measurement of operating leases liabilities |  | $ | 11,914 |  |  | $ | 9,346 |
Right-of-use assets obtained in exchange for operating lease obligations, net of early lease terminations (a) |  | $ | 24,427 |  |  | $ | 10,738 |

(a) Additions for the six months ended June 30, 2021, include $7.9 million of right-of-use assets obtained with the acquisition of ezyVet.
17

NOTE 9. OTHER CURRENT AND LONG-TERM ASSETS
Other current assets consisted of the following:

(in thousands) | June 30, 2021 |  | December 31, 2020
Customer acquisition costs | $ | 46,982 |  |  | $ | 43,751 |
Prepaid expenses | 33,227 |  |  | 34,556 |
Contract assets, net | 27,695 |  |  | 23,837 |
Taxes receivable | 17,383 |  |  | 19,476 |
Deferred sales commissions | 6,113 |  |  | 5,738 |
Other assets | 13,992 |  |  | 10,150 |
Other current assets | $ | 145,392 |  |  | $ | 137,508 |

Other long-term assets consisted of the following:

(in thousands) | June 30, 2021 |  | December 31, 2020
Customer acquisition costs | $ | 108,317 |  |  | $ | 104,369 |
Contract assets, net | 106,962 |  |  | 91,681 |
Deferred income taxes | 26,770 |  |  | 31,549 |
Deferred sales commissions | 12,291 |  |  | 11,719 |
Investment in long-term product supply arrangements | 10,489 |  |  | 12,065 |
Taxes receivable | 2,450 |  |  | 6,329 |
Other assets | 38,067 |  |  | 31,883 |
Other long-term assets | $ | 305,346 |  |  | $ | 289,595 |

NOTE 10. ACCRUED LIABILITIES
Accrued liabilities consisted of the following:

(in thousands) | June 30, 2021 |  | December 31, 2020
Accrued employee compensation and related expenses | 136,331 |  |  | 167,649 |
Accrued expenses | $ | 112,388 |  |  | $ | 112,526 |
Accrued customer incentives and refund obligations | 85,299 |  |  | 75,064 |
Accrued taxes | 39,428 |  |  | 42,676 |
Current lease liabilities | 19,235 |  |  | 17,733 |
Accrued liabilities | $ | 392,681 |  |  | $ | 415,648 |

Other long-term liabilities consisted of the following:

(in thousands) | June 30, 2021 |  | December 31, 2020
Accrued taxes | $ | 58,129 |  |  | $ | 60,313 |
Other accrued long-term expenses | 26,914 |  |  | 25,291 |
Other long-term liabilities | $ | 85,043 |  |  | $ | 85,604 |

18

NOTE 11. REPURCHASES OF COMMON STOCK
We primarily acquire shares by repurchases in the open market. However, we also acquire shares that are surrendered by employees in payment for the minimum required statutory withholding taxes due on the vesting of restricted stock units and the settlement of deferred stock units, otherwise referred to herein as employee surrenders. We issue shares of treasury stock upon the vesting of certain restricted stock units and upon the exercise of certain stock options. The number of shares of treasury stock issued during the three and six months ended June 30, 2021 and 2020 was not material.
The following is a summary of our open market common stock repurchases, reported on a trade date basis, and shares acquired through employee surrender:

(in thousands, except per share amounts) | For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
Shares repurchased in the open market | 341 |  |  | — |  |  | 618 |  |  | 721 |
Shares acquired through employee surrender for statutory tax withholding (1) | — |  |  | — |  |  | 28 |  |  | 30 |
Total shares repurchased | 341 |  |  | — |  |  | 646 |  |  | 751 |
Cost of shares repurchased in the open market | $ | 188,409 |  |  | $ | — |  |  | $ | 327,622 |  |  | $ | 179,623 |
Cost of shares for employee surrenders | 3 |  |  | 65 |  |  | 14,986 |  |  | 8,669 |
Total cost of shares | $ | 188,412 |  |  | $ | 65 |  |  | $ | 342,608 |  |  | $ | 188,292 |
Average cost per share - open market repurchases | $ | 552.08 |  |  | $ | — |  |  | $ | 529.45 |  |  | $ | 249.20 |
Average cost per share - employee surrenders | $ | 550.59 |  |  | $ | 312.19 |  |  | $ | 544.08 |  |  | $ | 288.94 |
Average cost per share - total | $ | 552.08 |  |  | $ | 312.19 |  |  | $ | 530.07 |  |  | $ | 250.79 |

(1) For the quarters ended June 30, 2021 and 2020, the number of shares acquired though employee surrender for statutory tax withholding were below rounding thresholds.
NOTE 12. INCOME TAXES
Our effective income tax rate was 19.5% for the three months ended June 30, 2021, as compared to 18.9% for the three months ended June 30, 2020, and 17.3% for the six months ended June 30, 2021, as compared to 18.6% for the six months ended June 30, 2020.The increase in our effective tax rate for the three months ended June 30, 2021, as compared to the same period in the prior year, was primarily due to changes in the regional earnings mix. The decrease in our effective tax rate for the six months ended June 30, 2021, as compared to the same period in the prior year, was primarily driven by an overall increase in tax benefits from share-based compensation.
The effective tax rate for the three and six months ended June 30, 2021, differed from the U.S. statutory tax rate of 21% primarily due to tax benefits from share-based compensation.
19

NOTE 13. ACCUMULATED OTHER COMPREHENSIVE INCOME
The changes in AOCI, net of tax, consisted of the following:

|  | For the Six Months Ended June 30, 2021
|  |  |  | Unrealized Gain (Loss) on Cash Flow Hedges, Net of Tax |  | Unrealized (Loss) Gain on Net Investment Hedges, Net of Tax |  |  |  |
(in thousands) |  | Unrealized Gain (Loss) on Investments, Net of Tax |  | Foreign Currency Exchange Contracts |  | Euro-Denominated Notes |  | Cross Currency Swaps |  | Cumulative Translation Adjustment |  | Total
Balance as of December 31, 2020 |  | $ | (272) |  |  | $ | (9,934) |  |  | $ | (5,982) |  |  | $ | (2,159) |  |  | $ | (35,268) |  |  | $ | (53,615) |
Other comprehensive income (loss) before reclassifications |  | 154 |  |  | 3,191 |  |  | 2,654 |  |  | 2,202 |  |  | (7,246) |  |  | 955 |
Loss reclassified from accumulated other comprehensive income |  | — |  |  | 4,269 |  |  | — |  |  | — |  |  | — |  |  | 4,269 |
Balance as of June 30, 2021 |  | $ | (118) |  |  | $ | (2,474) |  |  | $ | (3,328) |  |  | $ | 43 |  |  | $ | (42,514) |  |  | $ | (48,391) |

|  | For the Six Months Ended June 30, 2020
|  |  |  | Unrealized Gain (Loss) on Cash Flow Hedges, Net of Tax |  | Unrealized Gain (Loss) on Net Investment Hedges, Net of Tax |  |  |  |
(in thousands) |  | Unrealized (Loss) Gain on Investments, Net of Tax |  | Foreign Currency Exchange Contracts |  | Euro-Denominated Notes |  | Cross Currency Swaps |  | Cumulative Translation Adjustment |  | Total
Balance as of December 31, 2019 |  | $ | 110 |  |  | $ | (736) |  |  | $ | 1,396 |  |  | $ | 3,467 |  |  | $ | (50,419) |  |  | $ | (46,182) |
Other comprehensive (loss) income before reclassifications |  | (574) |  |  | 5,538 |  |  | (642) |  |  | 2,602 |  |  | (15,200) |  |  | (8,276) |
Gain reclassified from accumulated other comprehensive income |  | — |  |  | (2,574) |  |  | — |  |  | — |  |  | — |  |  | (2,574) |
Balance as of June 30, 2020 |  | $ | (464) |  |  | $ | 2,228 |  |  | $ | 754 |  |  | $ | 6,069 |  |  | $ | (65,619) |  |  | $ | (57,032) |

20

The following tables present components and amounts reclassified out of AOCI to net income:

(in thousands) |  | Affected Line Item in the Statements of Income |  | Amounts Reclassified from AOCI For the Three Months Ended June 30,
|  |  |  | 2021 |  | 2020
Gain (loss) on derivative instruments classified as cash flow hedges included in net income: |  |  |  |  |  |
Foreign currency exchange contracts |  | Cost of revenue |  | $ | (2,715) |  |  | $ | 1,812 |
|  | Tax expense (benefit) |  | (340) |  |  | 339 |
|  | Gain (loss), net of tax |  | $ | (2,375) |  |  | $ | 1,473 |

(in thousands) |  | Affected Line Item in the Statements of Income |  | Amounts Reclassified from AOCI For the Six Months Ended June 30,
|  |  |  | 2021 |  | 2020
Gain (loss) on derivative instruments classified as cash flow hedges included in net income: |  |  |  |  |  |
Foreign currency exchange contracts |  | Cost of revenue |  | $ | (5,145) |  |  | $ | 3,153 |
|  | Tax expense (benefit) |  | (876) |  |  | 579 |
|  | Gain (loss), net of tax |  | $ | (4,269) |  |  | $ | 2,574 |

NOTE 14. EARNINGS PER SHARE
Basic earnings per share is computed by dividing net income attributable to our stockholders by the weighted average number of shares of common stock and vested deferred stock units outstanding during the year. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and assumed issuance of unvested restricted stock units and unvested deferred stock units using the treasury stock method unless the effect is anti-dilutive. The treasury stock method assumes that proceeds, including cash received from the exercise of employee stock options and the total unrecognized compensation expense for unvested share-based compensation awards, would be used to purchase our common stock at the average market price during the period. Vested deferred stock units outstanding are included in shares outstanding for basic and diluted earnings per share because the associated shares of our common stock are issuable for no cash consideration, the number of shares of our common stock to be issued is fixed, and issuance is not contingent. See Note 5 to the consolidated financial statements in our 2020 Annual Report for additional information regarding deferred stock units.
The following is a reconciliation of weighted average shares outstanding for basic and diluted earnings per share:

(in thousands) | For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
Shares outstanding for basic earnings per share | 85,325 |  |  | 85,134 |  |  | 85,427 |  |  | 85,282 |
Shares outstanding for diluted earnings per share: |  |  |  |  |  |  |
Shares outstanding for basic earnings per share | 85,325 |  |  | 85,134 |  |  | 85,427 |  |  | 85,282 |
Dilutive effect of share-based payment awards | 1,329 |  |  | 1,268 |  |  | 1,367 |  |  | 1,286 |
| 86,654 |  |  | 86,402 |  |  | 86,794 |  |  | 86,568 |

21

Certain awards and options to acquire shares have been excluded from the calculation of shares outstanding for diluted earnings per share because they were anti-dilutive. The following table presents information concerning those anti-dilutive awards and options:

(in thousands) | For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
Weighted average number of shares underlying anti-dilutive awards | — |  | — |  | 1 |  | 1
Weighted average number of shares underlying anti-dilutive options | 135 |  |  | 270 |  |  | 102 |  | 218

NOTE 15. COMMITMENTS, CONTINGENCIES AND GUARANTEES
Commitments
See “Note 8. Leases”, for more information regarding our lease commitments.
Contingencies and Guarantees
We are subject to claims that may arise in the ordinary course of business, including with respect to actual and threatened litigation and other matters. We accrue for loss contingencies when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. However, the results of legal actions cannot be predicted with certainty, and therefore our actual losses with respect to these contingencies could be higher and lower than our accruals. Except for the litigation matter described below, at June 30, 2021, our accruals with respect to actual and threatened litigation were not material.
We are a defendant in an ongoing litigation matter involving an alleged breach of contract for underpayment of royalty payments made from 2004 through 2017 under an expired patent license agreement. The plaintiff has asserted a claim of approximately $50 million, inclusive of interest, alleging that the incorrect royalty provision was applied to certain licensed products and services throughout the agreement term and that royalties were also due on non-licensed diagnostic services that were provided concurrently with licensed services. The trial court has ruled in favor of the plaintiff in this matter and we are appealing the judgment and continue to vigorously defend ourselves against the plaintiff’s allegations. While we believe the claim is without merit, litigation is inherently unpredictable and there can be no assurance that we will prevail in this matter. During the third quarter of 2020, we established an accrual of $27.5 million related to this ongoing matter, which represents the amount of a possible loss that we have determined to be probable and estimable. We have not made any adjustments to this accrual since it was established. The actual cost of resolving this matter may be higher or lower than the amount we have accrued.
From time to time, we have received notices alleging that our products infringe third-party proprietary rights, although we are not aware of any pending litigation with respect to such claims. Patent litigation frequently is complex and expensive, and the outcome of patent litigation can be difficult to predict. There can be no assurance that we will prevail in any infringement proceedings that may be commenced against us. If we lose any such litigation, we may be stopped from selling certain products and/or we may be required to pay damages as a result of the litigation.
We have had no significant changes to our contingencies and guarantees discussed in Note 16 to the consolidated financial statements in our 2020 Annual Report.
22

NOTE 16. SEGMENT REPORTING
Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker (“CODM”), or decision-making group, in deciding how to allocate resources and in assessing performance. Our CODM is our Chief Executive Officer. Our reportable segments include diagnostic and information technology-based products and services for the veterinary market, which we refer to as the Companion Animal Group (“CAG”), water quality products (“Water”) and diagnostic products and services for livestock and poultry health and to ensure the quality and safety of milk and improve dairy efficiency, which we refer to as Livestock, Poultry and Dairy (“LPD”). Although our LPD segment does not meet the quantitative thresholds to be reported as a separate segment, we believe it is important to disaggregate these revenues as a major product and service category within our Other reportable segment given its distinct markets, and therefore we have elected to report LPD as a reportable segment. Our Other operating segment combines and presents products and services for the human medical diagnostics (“OPTI Medical”) market with our out-licensing arrangements. Assets are not allocated to segments for internal reporting purposes.
The following is a summary of segment performance:

(in thousands) |  | For the Three Months Ended June 30,
|  | CAG |  | Water |  | LPD |  | Other |  | Consolidated Total
2021 |  |  |  |  |  |  |  |  |  |
Revenue |  | $ | 745,595 |  |  | $ | 37,191 |  |  | $ | 33,524 |  |  | $ | 9,832 |  |  | $ | 826,142 |
Income from operations |  | $ | 234,735 |  |  | $ | 17,228 |  |  | $ | 6,868 |  |  | $ | 422 |  |  | $ | 259,253 |
Interest expense, net |  |  |  |  |  |  |  |  |  | (7,522) |
Income before provision for income taxes |  |  |  |  |  |  |  |  |  | 251,731 |
Provision for income taxes |  |  |  |  |  |  |  |  |  | 49,125 |
Net income |  |  |  |  |  |  |  |  |  | 202,606 |
Less: Net income attributable to noncontrolling interest |  |  |  |  |  |  |  |  |  | 24 |
Net income attributable to IDEXX Laboratories, Inc. stockholders |  |  |  |  |  |  |  |  |  | $ | 202,582 |
2020 |  |  |  |  |  |  |  |  |  |
Revenue |  | $ | 566,100 |  |  | $ | 28,116 |  |  | $ | 32,244 |  |  | $ | 11,132 |  |  | $ | 637,592 |
Income from operations |  | $ | 167,969 |  |  | $ | 12,258 |  |  | $ | 8,249 |  |  | $ | 4,772 |  |  | $ | 193,248 |
Interest expense, net |  |  |  |  |  |  |  |  |  | (9,426) |
Income before provision for income taxes |  |  |  |  |  |  |  |  |  | 183,822 |
Provision for income taxes |  |  |  |  |  |  |  |  |  | 34,826 |
Net income |  |  |  |  |  |  |  |  |  | 148,996 |
Less: Net income attributable to noncontrolling interest |  |  |  |  |  |  |  |  |  | 56 |
Net income attributable to IDEXX Laboratories, Inc. stockholders |  |  |  |  |  |  |  |  |  | $ | 148,940 |

23

(in thousands) |  | For the Six Months Ended June 30,
|  | CAG |  | Water |  | LPD |  | Other |  | Consolidated Total
2021 |  |  |  |  |  |  |  |  |  |
Revenue |  | $ | 1,438,362 |  |  | $ | 71,231 |  |  | $ | 72,794 |  |  | $ | 21,462 |  |  | $ | 1,603,849 |
Income from operations |  | $ | 447,945 |  |  | $ | 32,000 |  |  | $ | 20,676 |  |  | $ | 6,254 |  |  | $ | 506,875 |
Interest expense, net |  |  |  |  |  |  |  |  |  | (15,054) |
Income before provision for income taxes |  |  |  |  |  |  |  |  |  | 491,821 |
Provision for income taxes |  |  |  |  |  |  |  |  |  | 84,926 |
Net income |  |  |  |  |  |  |  |  |  | 406,895 |
Less: Net income attributable to noncontrolling interest |  |  |  |  |  |  |  |  |  | 56 |
Net income attributable to IDEXX Laboratories, Inc. stockholders |  |  |  |  |  |  |  |  |  | $ | 406,839 |
2020 |  |  |  |  |  |  |  |  |  |
Revenue |  | $ | 1,118,096 |  |  | $ | 62,265 |  |  | $ | 66,398 |  |  | $ | 17,169 |  |  | $ | 1,263,928 |
Income from operations |  | $ | 286,628 |  |  | $ | 28,140 |  |  | $ | 17,912 |  |  | $ | 4,893 |  |  | $ | 337,573 |
Interest expense, net |  |  |  |  |  |  |  |  |  | (16,978) |
Income before provision for income taxes |  |  |  |  |  |  |  |  |  | 320,595 |
Provision for income taxes |  |  |  |  |  |  |  |  |  | 59,743 |
Net income |  |  |  |  |  |  |  |  |  | 260,852 |
Less: Net income attributable to noncontrolling interest |  |  |  |  |  |  |  |  |  | 85 |
Net income attributable to IDEXX Laboratories, Inc. stockholders |  |  |  |  |  |  |  |  |  | $ | 260,767 |

See “Note 3. Revenue Recognition” for a summary of disaggregated revenue by reportable segment and by major product and service category for the three and six months ended June 30, 2021 and 2020.
NOTE 17. FAIR VALUE MEASUREMENTS
U.S. GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. U.S. GAAP requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value.
We have certain financial assets and liabilities that are measured at fair value on a recurring basis, certain nonfinancial assets and liabilities that may be measured at fair value on a non-recurring basis and certain financial assets and liabilities that are not measured at fair value in our unaudited condensed consolidated balance sheets but for which we disclose the fair value. The fair value disclosures of these assets and liabilities are based on a three-level hierarchy, which is defined as follows:

Level 1 |  | Quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date.
Level 2 |  | Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 |  | Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. We did not have any transfers in or out of Level 3 of the fair value hierarchy during the three and six months ended June 30, 2021.
24

Our cross currency swap contracts are measured at fair value on a recurring basis in our accompanying unaudited condensed consolidated balance sheets. We measure the fair value of our cross currency swap contracts classified as derivative instruments using prevailing market conditions as of the close of business on each balance sheet date. The product of this calculation is then adjusted for counterparty risk.
Our foreign currency exchange contracts are measured at fair value on a recurring basis in our accompanying unaudited condensed consolidated balance sheets. We measure the fair value of our foreign currency exchange contracts classified as derivative instruments using an income approach, based on prevailing market forward rates less the contract rate multiplied by the notional amount. The product of this calculation is then adjusted for counterparty risk.
The amounts outstanding under our unsecured revolving credit facility (“Credit Facility” or “line of credit”) and senior notes (“long-term debt”) are measured at carrying value in our unaudited condensed consolidated balance sheets though we disclose the fair value of these financial instruments. We determine the fair value of the amount outstanding under our Credit Facility and long-term debt using an income approach, utilizing a discounted cash flow analysis based on current market interest rates for debt issues with similar remaining years to maturity, adjusted for applicable credit risk. Our Credit Facility and long-term debt are valued using Level 2 inputs. The estimated fai r value of our Credit Facility approximates its carrying value. The estimated fair value and carrying value of our long-term debt w ere $987.8 million and $905.6 million, respectively, as of June 30, 2021, and $1.0 billion and $909.1 million, respectively, as of December 31, 2020.
25

The following tables set forth our assets and liabilities that were measured at fair value on a recurring basis by level within the fair value hierarchy:

(in thousands) |  |  |  |  |  |  |  |
As of June 30, 2021 |  | Quoted Prices in Active Markets for Identical Assets (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Unobservable Inputs (Level 3) |  | Balance at June 30, 2021
Assets |  |  |  |  |  |  |  |
Money market funds (1) |  | $ | 76 |  |  | $ | — |  |  | $ | — |  |  | $ | 76 |
Equity mutual funds (2) |  | $ | 1,007 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,007 |
Cross currency swaps (3) |  | $ | — |  |  | $ | 54 |  |  | $ | — |  |  | $ | 54 |
Foreign currency exchange contracts (3) |  | $ | — |  |  | $ | 2,400 |  |  | $ | — |  |  | $ | 2,400 |
Liabilities |  |  |  |  |  |  |  |
Foreign currency exchange contracts (3) |  | $ | — |  |  | $ | 5,487 |  |  | $ | — |  |  | $ | 5,487 |
Deferred compensation(4) |  | $ | 1,007 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,007 |
Contingent payment- acquisitions |  | $ | — |  |  | $ | — |  |  | $ | 5,000 |  |  | $ | 5,000 |

(in thousands) |  |  |  |  |  |  |  |
As of December 31, 2020 |  | Quoted Prices in Active Markets for Identical Assets (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Unobservable Inputs (Level 3) |  | Balance at December 31, 2020
Assets |  |  |  |  |  |  |  |
Money market funds (1) |  | $ | 76 |  |  | $ | — |  |  | $ | — |  |  | $ | 76 |
Equity mutual funds (2) |  | $ | 1,145 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,145 |
Foreign currency exchange contracts (3) |  | $ | — |  |  | $ | 125 |  |  | $ | — |  |  | $ | 125 |
Liabilities |  |  |  |  |  |  |  |
Cross currency swaps (3) |  | $ | — |  |  | $ | 2,841 |  |  | $ | — |  |  | $ | 2,841 |
Foreign currency exchange contracts (3) |  | $ | — |  |  | $ | 12,373 |  |  | $ | — |  |  | $ | 12,373 |
Deferred compensation(4) |  | $ | 1,145 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,145 |

(1)Money market funds with an original maturity of less than ninety days are included within cash and cash equivalents. The remaining balance of cash and cash equivalents as of June 30, 2021 and December 31, 2020, consisted of demand deposits.
(2)Equity mutual funds relate to a deferred compensation plan that was assumed as part of a previous business combination. This amount is included within other long-term assets. See footnote (4) below for a discussion of the related deferred compensation liability.
(3)Cross currency swaps and foreign currency exchange contracts are included within other current assets, other long-term assets, accrued liabilities, or other long-term liabilities depending on the gain (loss) position and anticipated settlement date.
(4)A deferred compensation plan assumed as part of a previous business combination is included within accrued liabilities and other long-term liabilities. The fair value of our deferred compensation plan is indexed to the performance of the underlying equity mutual funds discussed in footnote (2) above.
We have classified our liability for contingent consideration related to acquisitions within Level 3 of the fair value hierarchy because the fair value is determined using significant unobservable inputs, which includes the achievements of future revenues. The contingent consideration is included within other long-term liabilities.
The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate carrying value due to their short maturity.
26

NOTE 18. HEDGING INSTRUMENTS
Disclosure within this note is presented to provide transparency about how and why we use derivative and non-derivative instruments (collectively “hedging instruments”), how the instruments and related hedged items are accounted for, and how the instruments and related hedged items affect our financial position, results of operations and cash flows.
We are exposed to certain risks related to our ongoing business operations. The primary risk that we currently manage by using hedging instruments is foreign currency exchange risk. We may also enter into interest rate swaps to minimize the impact of interest rate fluctuations associated with borrowings under our variable-rate Credit Facility.
Our subsidiaries enter into foreign currency exchange contracts to manage the exchange risk associated with their forecasted intercompany inventory purchases and sales for the next year. From time to time, we may also enter into other foreign currency exchange contracts, cross currency swaps or foreign-denominated debt issuances to minimize the impact of foreign currency fluctuations associated with specific balance sheet exposures, including net investments in certain foreign subsidiaries.
The primary purpose of our foreign currency hedging activities is to protect against the volatility associated with foreign currency transactions, including transactions denominated in the euro, British pound, Japanese yen, Canadian dollar, and Australian dollar. We also utilize natural hedges to mitigate our transaction and commitment exposures. Our corporate policy prescribes the range of allowable hedging activity. We enter into foreign currency exchange contracts with well-capitalized multinational financial institutions, and we do not hold or engage in transactions involving derivative instruments for purposes other than risk management. Our accounting policies for these contracts are based on the designation of such instruments as hedging transactions.
We recognize all hedging instruments on the balance sheet at fair value at the balance sheet date. Instruments that do not qualify for hedge accounting treatment must be recorded at fair value through earnings. To qualify for hedge accounting treatment, cash flow and net investment hedges must be highly effective in offsetting changes to expected future cash flows or fair value on hedged transactions. If the instrument qualifies for hedge accounting, changes in the fair value of the hedging instrument from the effective portion of the hedge are deferred in AOCI, net of tax, and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. We immediately record in earnings the extent to which a hedging instrument is not effective in achieving offsetting changes in fair value. We de-designate hedging instruments from hedge accounting when the likelihood of the hedged transaction occurring becomes less than probable. For de-designated instruments, the gain or loss from the time of de-designation through maturity of the instrument is recognized in earnings. Any gain or loss in AOCI at the time of de-designation is reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. See “Note 13. Accumulated Other Comprehensive Income” for further information regarding the effect of hedging instruments on our unaudited condensed consolidated statements of income for the three and six months ended June 30, 2021 and 2020.
We enter into master netting arrangements with the counterparties to our derivative transactions which permit certain outstanding receivables and payables to be offset in the event of default. Our derivative contracts do not require either party to post cash collateral. We elect to present our derivative assets and liabilities in the unaudited condensed consolidated balance sheets on a gross basis. All cash flows related to our foreign currency exchange contracts are classified as operating cash flows, which is consistent with the cash flow treatment of the underlying items being hedged.
Cash Flow Hedges
We have designated our foreign currency exchange contracts as cash flow hedges as these derivative instruments mitigate the exposure to variability in the cash flows of forecasted transactions attributable to foreign currency exchange. Unless noted otherwise, we have also designated our derivative instruments as qualifying for hedge accounting treatment.
We did not de-designate any instruments from hedge accounting treatment during either the three and six months ended June 30, 2021 or 2020. At June 30, 2021, the estimated amount of net losses, net of tax, which are expected to be reclassified out of AOCI and into earnings within the next 12 months, is $2.9 million if exchange rates do not fluctuate from the levels at June 30, 2021.
We target to hedge approximately 85% of the estimated exposure from intercompany product purchases and sales denominated in the euro, British pound, Canadian dollar, Japanese yen, and Australian dollar. We have additional unhedged foreign currency exposures related to foreign services and emerging markets where it is not practical to hedge. We primarily utilize foreign currency exchange contracts with durations of less than 24 months. Quarterly, we enter into contracts to hedge
27

incremental portions of anticipated foreign currency transactions for the current and following year. As a result, our risk with respect to foreign currency exchange rate fluctuations and the notional value of foreign currency exchange contracts may vary throughout the year. The U.S. dollar is the currency purchased or sold in all of our foreign currency exchange contracts. The notional amount of foreign currency exchange contracts to hedge forecasted intercompany inventory purchases and sales totaled $210.2 million and $202.7 million at June 30, 2021 and December 31, 2020, respectively.
The following tables present the effect of cash flow hedge accounting on our unaudited condensed consolidated statements of income and comprehensive income, and provide information regarding the location and amounts of pretax gains or losses of derivatives:

(in thousands) |  |  |  | Three Months Ended June 30,
|  |  |  | 2021 |  | 2020
Financial statement line items in which effects of cash flow hedges are recorded |  | Cost of revenue |  | $ | 336,834 |  |  | $ | 258,250 |
Foreign exchange contracts |  |  |  |  |  |
Amount of (loss) gain reclassified from accumulated other comprehensive income into income |  |  |  | $ | (2,715) |  |  | $ | 1,812 |

(in thousands) |  |  |  | Six Months Ended June 30,
|  |  |  | 2021 |  | 2020
Financial statement line items in which effects of cash flow hedges are recorded |  | Cost of revenue |  | $ | 643,759 |  |  | $ | 524,996 |
Foreign exchange contracts |  |  |  |  |  |
Amount of (loss) gain reclassified from accumulated other comprehensive income into income |  |  |  | $ | (5,145) |  |  | $ | 3,153 |

Net Investment Hedges, Euro-Denominated Notes
In June 2015, we issued and sold through a private placement an aggregate principal amount of €88.9 million in euro-denominated 1.785% Series C Senior Notes due June 18, 2025. We have designated these euro-denominated notes as a hedge of our euro net investment in certain foreign subsidiaries to reduce the volatility in stockholders’ equity caused by changes in foreign currency exchange rates in the euro relative to the U.S. dollar. As a result of this designation, gains and losses from the change in translated U.S. dollar value of these euro-denominated notes are recorded in AOCI rather than to earnings. We recorded losses of $1.0 million and gains of $2.7 million, net of tax, within AOCI as a result of this net investment hedge for the three and six months ended June 30, 2021, respectively, and losses of $1.7 million and $0.6 million for the three and six months ended June 30, 2020, respectively. The related cumulative unrealized loss recorded at June 30, 2021, will not be reclassified in earnings until the complete or substantially complete liquidation of the net investment in the hedged foreign operations or a portion of the hedge no longer qualifies for hedge accounting treatment. See Note 13 to the consolidated financial statements included in our 2020 Annual Report for further information regarding the issuance of these euro-denominated notes.
Net Investment Hedges, Cross Currency Swaps
We have entered into several cross currency swap contracts as a hedge of our net investment in foreign operations to offset foreign currency translation gains and losses on the net investment. These cross currency swaps have maturity dates beginning on June 30, 2023, through June 18, 2025. At maturity of the cross currency swap contracts, we will deliver the notional amount of €90.0 million and will receive approximately $104.5 million from the counterparties on June 30, 2023, and we will deliver the notional amount of €15 million and will receive approximately $17.5 million from the counterparties on June 18, 2025. The change in fair value of the cross currency swap contracts are recorded in AOCI and will be reclassified to earnings when the foreign subsidiaries are sold or substantially liquidate d. During the three and six months ended June 30, 2021, we recorded losses of $1.1 million and gains of $2.2 million, respectively, net of tax, within AOCI as a result of these net investment hedges, and losses of $1.4 million and gains of $2.6 million during the three and six months ended June 30, 2020, respectively. We will receive quarterly interest payments from the counterparties based on a fixed interest rate until maturity of the cross currency swaps. This interest rate component is excluded from the assessment of hedge effectiveness and, thus is recognized as a reduction to interest expense over the life of the hedge instrument. We recognized ap proximately $0.7 million and $1.4 million related to the excluded component as a reduction of interest expense for the three and six months ended June 30, 2021, respectively, and $0.7 million and $1.3 million for the three and six months ended June 30, 2020, respectively.
28

Fair Values of Hedging Instruments Designated as Hedges in Consolidated Balance Sheets
The fair values of hedging instruments and their respective classification on our unaudited condensed consolidated balance sheets and amounts subject to offset under master netting arrangements consisted of the following derivative instruments, unless otherwise noted:

(in thousands) |  |  |  | Hedging Assets
|  |  |  | June 30, 2021 |  | December 31, 2020
Derivatives and non-derivatives designated as hedging instruments |  | Balance Sheet Classification |  |  |  |
Foreign currency exchange contracts |  | Other current assets |  | $ | 1,676 |  |  | $ | 125 |
Cross currency swaps |  | Other long-term assets |  | 54 |  |  | — |
Foreign currency exchange contracts |  | Other long-term assets |  | 724 |  |  | — |
Total derivative instruments presented as hedge instruments on the balance sheet |  |  |  | 2,454 |  |  | 125 |
Gross amounts subject to master netting arrangements not offset on the balance sheet |  |  |  | (2,010) |  |  | (125) |
Net amount |  |  |  | $ | 444 |  |  | $ | — |

(in thousands) |  |  |  | Hedging Liabilities
|  |  |  | June 30, 2021 |  | December 31, 2020
Derivatives and non-derivatives designated as hedging instruments |  | Balance Sheet Classification |  |  |  |
Foreign currency exchange contracts |  | Accrued liabilities |  | $ | 5,349 |  |  | $ | 12,373 |
Cross currency swaps |  | Other long-term liabilities |  | — |  |  | 2,841 |
Foreign currency exchange contracts |  | Other long-term liabilities |  | 138 |  |  | — |
Total derivative instruments presented as cash flow hedges on the balance sheet |  |  |  | 5,487 |  |  | 15,214 |
Non-derivative foreign currency denominated debt designated as net investment hedge on the balance sheet(1) |  | Long-term debt |  | 105,634 |  |  | 109,125 |
Total hedging instruments presented on the balance sheet |  |  |  | 111,121 |  |  | 124,339 |
Gross amounts subject to master netting arrangements not offset on the balance sheet |  |  |  | (2,010) |  |  | (125) |
Net amount |  |  |  | $ | 109,111 |  |  | $ | 124,214 |

(1) Amounts represent reported carrying amounts of our foreign currency denominated debt. See “Note 17. Fair Value Measurements” for information regarding the fair value of our long-term debt.
29

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
This Quarterly Report on Form 10-Q contains statements which, to the extent they are not statements of historical fact, constitute “forward-looking statements.” Such forward-looking statements about our business and expectations within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), include statements relating to, among other things, the impact of the COVID-19 pandemic; future revenue growth rates; revenue recognition timing and amounts; business trends, earnings and other measures of financial performance; the effect of economic downturns on our business performance; projected impact of foreign currency exchange rates; demand for our products; realizability of assets; future cash flow and uses of cash; future repurchases of common stock; future levels of indebtedness and capital spending, the working capital and liquidity outlook; the adoption and projected impact of new accounting standards; critical accounting estimates; deductibility of goodwill; future commercial efforts; and competition. Forward-looking statements can be identified by the use of words such as “expects,” “may,” “anticipates,” “intends,” “would,” “will,” “plans,” “believes,” “estimates,” “should,” “project,” and similar words and expressions. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including, among other things, the adverse impact, and the duration, of the effects of the ongoing COVID-19 pandemic on our business, results of operations, liquidity, financial condition, and stock price, as well as the other matters described under the headings “Business,” “Risk Factors,” “Legal Proceedings,” “Management's Discussion and Analysis of Financial Condition and Results of Operations,” and “Quantitative and Qualitative Disclosure About Market Risk” in our 2020 Annual Report and in the corresponding sections of this Quarterly Report on Form 10-Q for the quarters ended March 31, 2021, and June 30, 2021, as well as those described from time to time in our other periodic reports filed with the SEC.
Any forward-looking statements represent our estimates only as of the day this Quarterly Report on Form 10-Q was filed with the SEC and should not be relied upon as representing our estimates as of any subsequent date. From time to time, oral or written forward-looking statements may also be included in other materials released to the public. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates or expectations change.
You should read the following discussion and analysis in conjunction with our 2020 Annual Report that includes additional information about us, our results of operations, our financial position, and our cash flows, and with our unaudited condensed consolidated financial statements and related notes included in Part I. Item 1. Financial Statements of this Quarterly Report on Form 10-Q.
Our fiscal quarter ended on June 30. Unless otherwise stated, the analysis and discussion of our financial condition and results of operations below, including references to growth and organic growth and increases and decreases, are being compared to the equivalent prior-year periods.
Business Overview
We develop, manufacture, and distribute products and provide services primarily for the companion animal veterinary, livestock, poultry and dairy, and water testing markets. We also design, manufacture, and distribute point of care and laboratory diagnostics for the human medical diagnostics market. Our primary products and services are:
•Point-of-care veterinary diagnostic products, comprising instruments, consumables, and rapid assay test kits;
•Veterinary reference laboratory diagnostic and consulting services;
•Practice management and diagnostic imaging systems and services used by veterinarians;
•Health monitoring, biological materials testing, laboratory diagnostic instruments and services used by the biomedical research community;
•Diagnostic, health-monitoring products for livestock, poultry, and dairy;
•Products that test water for certain microbiological contaminants; and
•Point-of-care electrolytes, blood gas analyzers, and SARS-CoV-2 RT-PCR (COVID-19 test) used in the human medical diagnostics market.
Operating Segments. We operate primarily through three business segments: diagnostic and information technology-based products and services for the veterinary market, which we refer to as the Companion Animal Group (“CAG”), water quality products (“Water”) and diagnostic products and services for livestock and poultry health and to ensure the quality and safety of milk and improve dairy reproductive efficiency, which we refer to as Livestock, Poultry and Dairy (“LPD”). Our
30

Other operating segment combines and presents products for the human medical diagnostics market (“OPTI Medical”) with our out-licensing arrangements because they do not meet the quantitative or qualitative thresholds for reportable segments.
CAG develops, designs, manufactures, and distributes products and performs services for veterinarians and the biomedical analytics market, primarily related to diagnostics and information management. Water develops, designs, manufactures, and distributes a range of products used in the detection of various microbiological parameters in water. LPD develops, designs, manufactures, and distributes diagnostic tests and related software and performs services that are used to manage the health status of livestock and poultry, to improve bovine reproductive efficiency, and to ensure the quality and safety of milk. OPTI Medical develops, designs, manufactures, and distributes point-of-care and laboratory diagnostics (including electrolyte and blood gas analyzers, COVID-19 PCR test, and related consumable products) for the human medical diagnostics market.
Effects of Certain Factors and Trends on Results of Operations
CAG Market Trends. Favorable global trends in companion animal healthcare continue to support high growth for CAG diagnostic products and services across regions. U.S. same-store clinical visit growth at veterinary practices was approximately 13% in the second quarter, reflecting year-over-year growth of approximately 11% in non-wellness visits and approximately 14% in wellness visits. These gains include benefits from comparisons to prior year impacts on demand related to the COVID-19 pandemic. Average same-store revenue growth at U.S. veterinary practices was approximately 16% in the second quarter, driven by high growth in healthcare services, including increased utilization of diagnostics. For the remainder of the current year, we expect to see lower levels of growth in U.S. clinical visits and CAG Diagnostic revenue, as compared to the second half of the prior year, which included initial pandemic impacts, including benefits in the third quarter of 2020 due to delayed demand from the prior quarter. Furthermore, the potential effects related to ongoing COVID-19 case management efforts are challenging to predict and may pressure future revenues in CAG and our other segments should enhanced or renewed social distancing policies and higher infection rates impact our customers in certain regions.
Other Market Trends. We anticipate reduced LPD revenues on a year-over-year comparison in the second half of 2021, as we compare to high prior-year demand for our African Swine Fever testing in China. We also expect that revenues from our China LPD business may decline in the second half of 2021 from the rebuilding of swine herds, lower pork prices, and changing government requirements related to live animal imports and livestock infectious disease programs.
Currency and Other Items
Currency Impact. See “Part I. Item 3. Quantitative and Qualitative Disclosures about Market Risk” included in this Quarterly Report on Form 10-Q for additional information regarding the impact of foreign currency exchange rates.
Other Items. See “Part I. Item 1. Business - Patents and Licenses” and “Part II. Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2020 Annual Report for additional information regarding distributor purchasing and inventories, economic conditions, and patent expiration.
Critical Accounting Estimates and Assumptions
The discussion and analysis of our financial condition and results of operations is based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis. We base our estimates on historical experience and on various assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The critical accounting policies and the significant judgments and estimates used in the preparation of our unaudited condensed consolidated financial statements for the three and six months ended June 30, 2021, are consistent with those discussed in our 2020 Annual Report in the section under the heading “Part II. Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Estimates and Assumptions.”
Recent Accounting Pronouncements
For more information regarding the impact that recent accounting standards and amendments will have on our consolidated financial statements as described in Note 2 to the unaudited condensed consolidated financial statements in Part I. Item 1. Financial Statements of this Quarterly Report on Form 10-Q.
31

Non-GAAP Financial Measures
The following revenue analysis and discussion focuses on organic revenue growth, and references in this analysis and discussion to “revenue,” “revenues” or “revenue growth” are references to “organic revenue growth.” Organic revenue growth is a non-GAAP financial measure and represents the percentage change in revenue during the three and six months ended June 30, 2021, as compared to the same periods for the prior year, net of the effect of changes in foreign currency exchange rates, certain business acquisitions, and divestitures. Organic revenue growth should be considered in addition to, and not as a replacement for, or as a superior measure to, revenue growth reported in accordance with U.S. GAAP, and may not be comparable to similarly titled measures reported by other companies. Management believes that reporting organic revenue growth provides useful information to investors by facilitating easier comparisons of our revenue performance with prior and future periods and to the performance of our peers.
We exclude from organic revenue growth the effect of changes in foreign currency exchange rates because changes in foreign currency exchange rates are not under management’s control, are subject to volatility, and can obscure underlying business trends. We calculate the impact on revenue resulting from changes in foreign currency exchange rates by applying the difference between the weighted average exchange rates during the current year period and the comparable prior-year period to foreign currency denominated revenues for the prior-year period.
We also exclude from organic revenue growth the effect of certain business acquisitions and divestitures because the nature, size and number of these transactions can vary dramatically from period to period, and because they either require or generate cash as an inherent consequence of the transaction, and therefore can also obscure underlying business and operating trends. We exclude only acquisitions that are considered to be a business from organic revenue growth. In a business combination, if substantially all the fair value of the assets acquired is concentrated in a single asset or group of similar assets, we do not consider these assets to be a business and include these acquisitions in organic revenue growth. A typical acquisition that we do not consider a business is a customer list asset acquisition, which does not have all elements necessary to operate a business, such as employees or infrastructure. We believe the efforts required to convert and retain these acquired customers are similar in nature to our existing customer base and therefore are included in organic revenue growth.
We also use Adjusted EBITDA, gross debt, net debt, gross debt to Adjusted EBITDA ratio and net debt to Adjusted EBITDA ratio, in this Quarterly Report on Form 10-Q, all of which are non-GAAP financial measures that should be considered in addition to, and not as a replacement for, financial measures presented according to U.S. GAAP. Management believes that reporting these non-GAAP financial measures provides supplemental analysis to help investors further evaluate our business performance and available borrowing capacity under our Credit Facility.
32

Results of Operations
Three Months Ended June 30, 2021, Compared to Three Months Ended June 30, 2020
Total Company. The following table presents total Company revenue by operating segment:

|  | For the Three Months Ended June 30, |  |  |  |  |  |  |  |  |  |
Net Revenue (dollars in thousands) |  | 2021 |  | 2020 |  | Dollar Change |  | Reported Revenue Growth(1) |  | Percentage Change from Currency |  | Percentage Change from Acquisitions |  | Organic Revenue Growth(1)
CAG |  | $ | 745,595 |  |  | $ | 566,100 |  |  | $ | 179,495 |  |  | 31.7 | % |  | 3.7 | % |  | 0.6 | % |  | 27.4 | %
United States |  | 486,252 |  |  | 387,113 |  |  | 99,139 |  |  | 25.6 | % |  | — |  |  | 0.6 | % |  | 25.0 | %
International |  | 259,343 |  |  | 178,987 |  |  | 80,356 |  |  | 44.9 | % |  | 12.0 | % |  | 0.6 | % |  | 32.3 | %
Water |  | 37,191 |  |  | 28,116 |  |  | 9,075 |  |  | 32.3 | % |  | 5.7 | % |  | — |  |  | 26.6 | %
United States |  | 17,747 |  |  | 13,935 |  |  | 3,812 |  |  | 27.4 | % |  | — |  |  | — |  |  | 27.4 | %
International |  | 19,444 |  |  | 14,181 |  |  | 5,263 |  |  | 37.1 | % |  | 11.2 | % |  | — |  |  | 25.9 | %
LPD |  | 33,524 |  |  | 32,244 |  |  | 1,280 |  |  | 4.0 | % |  | 5.9 | % |  | — |  |  | (2.0 | %)
United States |  | 3,516 |  |  | 3,242 |  |  | 274 |  |  | 8.4 | % |  | — |  |  | — |  |  | 8.4 | %
International |  | 30,008 |  |  | 29,002 |  |  | 1,006 |  |  | 3.5 | % |  | 6.5 | % |  | — |  |  | (3.1 | %)
Other |  | 9,832 |  |  | 11,132 |  |  | (1,300) |  |  | (11.7 | %) |  | 4.5 | % |  | — |  |  | (16.2 | %)
Total Company |  | $ | 826,142 |  |  | $ | 637,592 |  |  | $ | 188,550 |  |  | 29.6 | % |  | 3.9 | % |  | 0.5 | % |  | 25.1 | %
United States |  | 515,238 |  |  | 405,998 |  |  | 109,240 |  |  | 26.9 | % |  | — |  |  | 0.6 | % |  | 26.3 | %
International |  | 310,904 |  |  | 231,594 |  |  | 79,310 |  |  | 34.2 | % |  | 10.7 | % |  | 0.5 | % |  | 23.1 | %

(1)Reported revenue growth and organic revenue growth may not recalculate due to rounding.
Total Company Revenue. The increase in both U.S. and international organic revenues was driven by strong volume gains in CAG Diagnostics recurring revenue, reflecting continued high demand for companion animal diagnostics globally, supported by an increase in clinical visits and diagnostic utilization per clinical visit, as compared to the second quarter of the prior year, which included initial pandemic impacts. Our CAG Diagnostics instrument revenue reflects high placement volume this quarter, as compared to the second quarter in the prior year, which was impacted by the global pandemic. In our LPD business, excluding the impact for currency movements, revenues decreased primarily as a result of lower swine and poultry testing in China, as well as lower heard health screening. The higher revenue in our Water business was the result of recovery of overall testing volumes including continued improvement in non-compliance testing volume that has been constrained during the pandemic and disruption in certain compliance testing during the second quarter of the prior year. Other revenues reflect lower demand, which has occurred as vaccination rates increase for human OPTI COVID-19 PCR test and services, which were introduced in the second quarter of 2020. The impact of currency movements increased total revenue by 3.9%, while acquisitions increased revenue by 0.5%.
33

The following table presents total Company results of operations:

|  | For the Three Months Ended June 30, |  | Change
Total Company - Results of Operations (dollars in thousands) |  | 2021 |  | Percent of Revenue |  | 2020 |  | Percent of Revenue |  | Amount |  | Percentage
Revenues |  | $ | 826,142 |  |  |  |  | $ | 637,592 |  |  |  |  | $ | 188,550 |  |  | 29.6 | %
Cost of revenue |  | 336,834 |  |  |  |  | 258,250 |  |  |  |  | 78,584 |  |  | 30.4 | %
Gross profit |  | 489,308 |  |  | 59.2 | % |  | 379,342 |  |  | 59.5 | % |  | 109,966 |  |  | 29.0 | %
Operating Expenses: |  |  |  |  |  |  |  |  |  |  |  |
Sales and marketing |  | 119,032 |  |  | 14.4 | % |  | 94,181 |  |  | 14.8 | % |  | 24,851 |  |  | 26.4 | %
General and administrative |  | 73,326 |  |  | 8.9 | % |  | 60,268 |  |  | 9.5 | % |  | 13,058 |  |  | 21.7 | %
Research and development |  | 37,697 |  |  | 4.6 | % |  | 31,645 |  |  | 5.0 | % |  | 6,052 |  |  | 19.1 | %
Total operating expenses |  | 230,055 |  |  | 27.8 | % |  | 186,094 |  |  | 29.2 | % |  | 43,961 |  |  | 23.6 | %
Income from operations |  | $ | 259,253 |  |  | 31.4 | % |  | $ | 193,248 |  |  | 30.3 | % |  | $ | 66,005 |  |  | 34.2 | %

Gross Profit. Gross profit increased due to higher sales volumes despite a modest 30 basis point decrease in the gross profit margin. The net decrease in the gross profit margin was driven by several factors including the mix impact from higher CAG Diagnostics instrument revenue and moderated laboratory productivity gains reflecting comparisons to tightly controlled prior year cost levels, as a response to the onset of the COVID-19 pandemic. These impacts were partially offset by the benefits of volume leverage in our CAG Diagnostics recurring revenue portfolio following the initial pandemic impacts in the second quarter of the prior year and moderate net price increases, as well as strong growth in veterinary software, services and diagnostics recurring revenues. The impact from foreign currency movements decreased the gross profit margin by less than 10 basis points, including the impact of hedge losses in the current year compared to hedge gains in the prior year.
Operating Expenses. Overall operating expenses were higher compared to the second quarter of 2020, during which cost containment efforts were implemented in response to the COVID-19 pandemic, including temporary reductions to compensation and benefits, and travel costs. Sales and marketing expense increased primarily due to higher personnel-related costs, including investments in our global commercial capability, as well as travel costs. General and administrative expense increased primarily due to higher personnel-related costs. Research and development expense increased primarily due to higher project and personnel-related costs. The overall change in currency exchange rates resulted in an increase in operating expenses of approximately 3%.
34

Companion Animal Group

The following table presents revenue by product and service category for CAG:

|  | For the Three Months Ended June 30, |  |  |  |  |  |
Net Revenue (dollars in thousands) |  | 2021 |  | 2020 |  | Dollar Change |  | Reported Revenue Growth (1) |  | Percentage Change from Currency |  | Percentage Change from Acquisitions |  | Organic Revenue Growth (1)
CAG Diagnostics recurring revenue: |  | $ | 661,300 |  |  | $ | 510,254 |  |  | $ | 151,046 |  |  | 29.6 | % |  | 3.7 | % |  | 0.3 | % |  | 25.6 | %
IDEXX VetLab consumables |  | 256,352 |  |  | 196,061 |  |  | 60,291 |  |  | 30.8 | % |  | 4.8 | % |  | — |  |  | 26.0 | %
Rapid assay products |  | 83,887 |  |  | 64,658 |  |  | 19,229 |  |  | 29.7 | % |  | 1.8 | % |  | — |  |  | 28.0 | %
Reference laboratory diagnostic and consulting services |  | 293,675 |  |  | 228,816 |  |  | 64,859 |  |  | 28.3 | % |  | 3.2 | % |  | 0.6 | % |  | 24.5 | %
CAG diagnostics services and accessories |  | 27,386 |  |  | 20,719 |  |  | 6,667 |  |  | 32.2 | % |  | 4.7 | % |  | — |  |  | 27.5 | %
CAG Diagnostics capital - instruments |  | 35,054 |  |  | 18,871 |  |  | 16,183 |  |  | 85.8 | % |  | 7.5 | % |  | — |  |  | 78.3 | %
Veterinary software, services and diagnostic imaging systems |  | 49,241 |  |  | 36,975 |  |  | 12,266 |  |  | 33.2 | % |  | 1.5 | % |  | 5.8 | % |  | 25.9 | %
Net CAG revenue |  | $ | 745,595 |  |  | $ | 566,100 |  |  | $ | 179,495 |  |  | 31.7 | % |  | 3.7 | % |  | 0.6 | % |  | 27.4 | %

(1) Reported revenue growth and organic revenue growth may not recalculate due to rounding
CAG Diagnostics Recurring Revenue. We continue to see strong market demand for companion animal diagnostics globally across modalities, including an increase in clinical visits and high levels of growth in testing volumes following the initial pandemic impact, which constrained volumes beginning in mid-March through May 2020. This volume growth includes an increase in diagnostic utilization per clinical visit. The increase in CAG Diagnostics recurring revenue was primarily due to increased reference laboratory diagnostic services, volumes in IDEXX VetLab consumables, and rapid assay products, and to a lesser extent, higher realized prices. The impact of currency movements increased revenues by 3.7%.
The increase in IDEXX VetLab® consumables revenue was primarily due to higher sales volumes for our Catalyst® consumables and, to a lesser extent, ProCyte consumables. These increases were supported by an increase in testing utilization across regions, high customer retention levels and expansion of our global premium instrument installed base.
The increase in rapid assay revenue resulted primarily from higher SNAP® 4Dx Plus sales volumes and higher realized prices. Results reflected strong growth in all major regions.
The increase in reference laboratory diagnostic and consulting services revenue was primarily due to higher testing volumes in all major regions, as well as higher average unit sales prices. Acquisitions increased revenue by 0.6%.
The increase in CAG Diagnostics services and accessories revenue was primarily a result of the increase in our active installed base of instruments.
CAG Diagnostics Capital – Instrument Revenue. The increase in instrument revenue was primarily due to strong premium instrument placements globally, as compared to constrained placements in the second quarter of 2020, as a result of the global pandemic, due to restrictions on our sales professionals’ access to clinics and certain customers’ deferral of new instrument purchases, which resulted in lower sales volumes.
Veterinary Software, Services and Diagnostic Imaging Systems Revenue. The increase in revenue was primarily due to higher imaging system placements, specifically our ImageVue DR 30 platform, as compared to the second quarter of 2020 during which diagnostic imaging placements were lower due to restrictions on our sales professionals’ access to clinics and certain customers deferring purchase decisions as a result of the COVID-19 pandemic. We also had increased veterinary
35

software and diagnostic imaging subscription-based service revenue, due to increases in our active installed base, new diagnostic imaging instrument and veterinary software system placements, and higher realized prices on these service offerings. Acquisitions increased revenue 5.8%.
The following table presents the CAG segment results of operations:

|  | For the Three Months Ended June 30, |  | Change
Results of Operations (dollars in thousands) |  | 2021 |  | Percent of Revenue |  | 2020 |  | Percent of Revenue |  | Amount |  | Percentage
Revenues |  | $ | 745,595 |  |  |  |  | $ | 566,100 |  |  |  |  | $ | 179,495 |  |  | 31.7 | %
Cost of revenues |  | 304,809 |  |  |  |  | 231,633 |  |  |  |  | 73,176 |  |  | 31.6 | %
Gross profit |  | 440,786 |  |  | 59.1 | % |  | 334,467 |  |  | 59.1 | % |  | 106,319 |  |  | 31.8 | %
Operating Expenses: |  |  |  |  |  |  |  |  |  |  |  |
Sales and marketing |  | 109,151 |  |  | 14.6 | % |  | 86,096 |  |  | 15.2 | % |  | 23,055 |  |  | 26.8 | %
General and administrative |  | 64,134 |  |  | 8.6 | % |  | 53,533 |  |  | 9.5 | % |  | 10,601 |  |  | 19.8 | %
Research and development |  | 32,766 |  |  | 4.4 | % |  | 26,869 |  |  | 4.7 | % |  | 5,897 |  |  | 21.9 | %
Total operating expenses |  | 206,051 |  |  | 27.6 | % |  | 166,498 |  |  | 29.4 | % |  | 39,553 |  |  | 23.8 | %
Income from operations |  | $ | 234,735 |  |  | 31.5 | % |  | $ | 167,969 |  |  | 29.7 | % |  | $ | 66,766 |  |  | 39.7 | %

Gross Profit. Gross profit increased primarily due to higher sales volume. Increases in the gross profit margin were primarily due to the benefits of volume leverage and price increases in our CAG Diagnostics recurring revenue portfolio, including significant volume leverage within our reference laboratories, which was moderated in comparisons to the tightly controlled prior year cost levels within laboratory operations. Furthermore, we saw strong growth in veterinary software, services and diagnostic imaging recurring revenues, including the positive impact of acquisitions. These favorable factors were offset by the impact from product mix with higher CAG Diagnostics instrument reven ue, as well as an impairment of rental assets in certain regions. The impact from foreign currency movements increased the gross profit margin by less than 10 basis points, including the impact of hedge losses in the current year compared to hedge gains in the prior year.
Operating Expenses. Overall operating expenses were higher compared to the second quarter of 2020, during which cost containment efforts were implemented in response to the COVID-19 pandemic, including temporary reductions to compensation and benefits and travel costs. Sales and marketing expense increased primarily due to higher personnel-related costs, including investments in our global commercial capability, as well as travel costs. General and administrative expense increased primarily due to personnel-related costs. Research and development expense increased primarily due to increased project and personnel-related costs. The overall change in currency exchange rates increased operating expenses by approximately 2%.
36

Water

The following table presents the Water segment results of operations:

|  | For the Three Months Ended June 30, |  | Change
Results of Operations (dollars in thousands) |  | 2021 |  | Percent of Revenue |  | 2020 |  | Percent of Revenue |  | Amount |  | Percentage
Revenues |  | $ | 37,191 |  |  |  |  | $ | 28,116 |  |  |  |  | $ | 9,075 |  |  | 32.3 | %
Cost of revenue |  | 11,444 |  |  |  |  | 8,438 |  |  |  |  | 3,006 |  |  | 35.6 | %
Gross profit |  | 25,747 |  |  | 69.2 | % |  | 19,678 |  |  | 70.0 | % |  | 6,069 |  |  | 30.8 | %
Operating Expenses: |  |  |  |  |  |  |  |  |  |  |  |
Sales and marketing |  | 4,099 |  |  | 11.0 | % |  | 3,399 |  |  | 12.1 | % |  | 700 |  |  | 20.6 | %
General and administrative |  | 3,384 |  |  | 9.1 | % |  | 3,193 |  |  | 11.4 | % |  | 191 |  |  | 6.0 | %
Research and development |  | 1,036 |  |  | 2.8 | % |  | 828 |  |  | 2.9 | % |  | 208 |  |  | 25.1 | %
Total operating expenses |  | 8,519 |  |  | 22.9 | % |  | 7,420 |  |  | 26.4 | % |  | 1,099 |  |  | 14.8 | %
Income from operations |  | $ | 17,228 |  |  | 46.3 | % |  | $ | 12,258 |  |  | 43.6 | % |  | $ | 4,970 |  |  | 40.5 | %

Revenue. The increase in revenue was primarily a result of the continued improvement in overall testing volumes, including non-compliance testing volume that has b een constrained during the COVID-19 pandemic. The increase in revenues was also due to disruption in certain compliance testing areas during the second quarter of the prior year due to social distancing policies, including beach and pool closures, as well as the impact of customer stocking orders in the first quarter of 2020 ahead of the pandemic, that impacted second quarter 2020 volumes. The impact of currency movements increased revenue by approximately 5.7%.
Gross Profit. Gross profit increased due to higher sales volumes despite an 80 basis point decrease in the gross profit margin, which reflected a 110 basis point reduction due to foreign currency movements, including the impact of hedge losses in the current year compared to hedge gains in the prior year. Excluding currency impacts, the increase in gross profit margin reflected the net benefit of price increases and volume leverage.
Operating Expenses. Overall operating expenses were higher compared to the second quarter of 2020, during which cost containment efforts were implemented in response to the COVID-19 pandemic, including temporary reductions to compensation and benefits and travel costs. Sales and marketing and general and administrative expenses increased primarily due to higher personnel-related costs. Research and development expense increased primarily due to third-party costs. The overall change in currency exchange rates resulted in an increase in operating expenses of approximately 3%.
37

Livestock, Poultry and Dairy

The following table presents the LPD segment results of operations:

|  | For the Three Months Ended June 30, |  | Change
Results of Operations (dollars in thousands) |  | 2021 |  | Percent of Revenue |  | 2020 |  | Percent of Revenue |  | Amount |  | Percentage
Revenues |  | $ | 33,524 |  |  |  |  | $ | 32,244 |  |  |  |  | $ | 1,280 |  |  | 4.0 | %
Cost of revenue |  | 13,998 |  |  |  |  | 13,405 |  |  |  |  | 593 |  |  | 4.4 | %
Gross profit |  | 19,526 |  |  | 58.2 | % |  | 18,839 |  |  | 58.4 | % |  | 687 |  |  | 3.6 | %
Operating Expenses: |  |  |  |  |  |  |  |  |  |  |  |
Sales and marketing |  | 5,142 |  |  | 15.3 | % |  | 4,298 |  |  | 13.3 | % |  | 844 |  |  | 19.6 | %
General and administrative |  | 4,271 |  |  | 12.7 | % |  | 3,678 |  |  | 11.4 | % |  | 593 |  |  | 16.1 | %
Research and development |  | 3,245 |  |  | 9.7 | % |  | 2,614 |  |  | 8.1 | % |  | 631 |  |  | 24.1 | %
Total operating expenses |  | 12,658 |  |  | 37.8 | % |  | 10,590 |  |  | 32.8 | % |  | 2,068 |  |  | 19.5 | %
Income from operations |  | $ | 6,868 |  |  | 20.5 | % |  | $ | 8,249 |  |  | 25.6 | % |  | $ | (1,381) |  |  | (16.7 | %)

Revenue. T he favorable impact of foreign currency movements increased revenues 5.9%. Excluding the impact of currency, overall revenues decreased primarily due to lower swine testing volumes in China, as swine herds are rebuilt, pork prices are low, and government requirements change related to live animal imports and livestock infectious disease programs, in comparison to high prior-year demand for African Swine Fever testing. We anticipate these trends will continue to impact our revenues in China during the second half of 2021. These decreases were partially offset by higher bovine testing volumes in Europe and the Americas, as compared to pandemic impacts in the second quarter of the prior year.
Gross Profit. Gross profit increased due to higher sales volumes despite a 20 basis point decrease in the gross profit margin. Excluding currency impacts, the gross profit margin increased as a result of lower product costs due to product mix. The impact of currency movements, including the impact of hedge losses in the current year compared to hedge gains in the prior year, reduced the gross margin by approximately 90 basis points.
Operating Expenses. Overall operating expenses were higher compared to the second quarter of 2020, during which cost containment efforts were implemented in response to the COVID-19 pandemic, including temporary reductions to compensation and benefits and travel costs. S ales and marketing expense increased primarily due to higher travel and personnel-related costs. General and administrative expenses increased primarily due to higher personnel-related costs. Research and development expense increased primarily due to higher personnel-related costs and third-party development costs. The overall change in currency exchange rates resulted in an increase in operating expenses of approximately 4%.
38

Other
The following table presents the Other results of operations:

|  | For the Three Months Ended June 30, |  | Change
Results of Operations (dollars in thousands) |  | 2021 |  | Percent of Revenue |  | 2020 |  | Percent of Revenue |  | Amount |  | Percentage
Revenues |  | $ | 9,832 |  |  |  |  | $ | 11,132 |  |  |  |  | $ | (1,300) |  |  | (11.7 | %)
Cost of revenue |  | 6,583 |  |  |  |  | 4,774 |  |  |  |  | 1,809 |  |  | 37.9 | %
Gross profit |  | 3,249 |  |  | 33.0 | % |  | 6,358 |  |  | 57.1 | % |  | (3,109) |  |  | (48.9 | %)
Operating Expenses: |  |  |  |  |  |  |  |  |  |  |  |
Sales and marketing |  | 640 |  |  | 6.5 | % |  | 388 |  |  | 3.5 | % |  | 252 |  |  | 64.9 | %
General and administrative |  | 1,537 |  |  | 15.6 | % |  | (136) |  |  | (1.2 | %) |  | 1,673 |  |  | (1,230.1 | %)
Research and development |  | 650 |  |  | 6.6 | % |  | 1,334 |  |  | 12.0 | % |  | (684) |  |  | (51.3 | %)
Total operating expenses |  | 2,827 |  |  | 28.8 | % |  | 1,586 |  |  | 14.2 | % |  | 1,241 |  |  | 78.2 | %
Income from operations |  | $ | 422 |  |  | 4.3 | % |  | $ | 4,772 |  |  | 42.9 | % |  | $ | (4,350) |  |  | (91.2 | %)

Revenue. The decrease in revenue was primarily due to lower OPTI COVID-19 PCR testing products and services, as compared to the second quarter of 2020 when the COVID-19 product and services were introduced, partially offset by higher royalty revenue associated with intellectual property related to our former pharmaceutical product line and higher OPTI Medical consumables. We currently estimate that the future demand for our OPTI COVID-19 PCR testing products and services will be lower than prior periods, although it is difficult to project given the uncertain nature of the COVID-19 pandemic, including the spread of variants, rates of vaccinations, governmental and private institution testing requirements, and alternative suppliers. The impact of currency movements on revenue was 4.5%.
Gross Profit. The decrease in gross profit was primarily due to lower sales volumes of our OPTI COVID-19 PCR testing products and services and a 2,410 basis point decrease in the gross profit margin, primarily due to higher product costs associated with write-downs of excess COVID-19 testing inventory, partially offset by the benefits of mix due to higher royalty revenue associated with our former pharmaceutical product line. The overall change in currency exchange rates had an immaterial impact on gross profit.
Operating Expenses. Sales and marketing expense increased primarily due to higher personnel-related costs. General and administrative expense increased primarily due to foreign exchange losses on settlements of foreign currency denominated transactions, as compared to gains in the prior year, for all operating segments, which are reported within our Other segment. Research and development expense decreased primarily due to lower project costs associated with the development of the OPTI COVID-19 PCR test.
Non-Operating Items
Interest Expense. Interest expense was $7.6 million for the three months ended June 30, 2021, as compared to $9.5 million for the same period in the prior year. The decrease in interest expense was primarily the result of lower average debt levels.
Provision for Income Taxes. Our effective income tax rate was 19.5% for the three months ended June 30, 2021, as compared to 18.9% for the three months ended June 30, 2020. The increase in our effective tax rate was primarily due to changes in the regional earnings mix.
39

Results of Operations
Six Months Ended June 30, 2021, Compared to Six Months Ended June 30, 2020
Total Company. The following table presents total Company revenue by operating segment:

|  | For the Six Months Ended June 30, |  |  |  |  |  |  |  |  |  |
Net Revenue (dollars in thousands) |  | 2021 |  | 2020 |  | Dollar Change |  | Reported Revenue Growth (1) |  | Percentage Change from Currency |  | Percentage Change from Acquisitions |  | Organic Revenue Growth (1)
CAG |  | $ | 1,438,362 |  |  | $ | 1,118,096 |  |  | $ | 320,266 |  |  | 28.6 | % |  | 3.3 | % |  | 0.4 | % |  | 25.0 | %
United States |  | 930,662 |  |  | 760,388 |  |  | 170,274 |  |  | 22.4 | % |  | — |  |  | 0.4 | % |  | 22.0 | %
International |  | 507,700 |  |  | 357,708 |  |  | 149,992 |  |  | 41.9 | % |  | 10.8 | % |  | 0.4 | % |  | 30.7 | %
Water |  | 71,231 |  |  | 62,265 |  |  | 8,966 |  |  | 14.4 | % |  | 3.7 | % |  | — |  |  | 10.7 | %
United States |  | 34,315 |  |  | 30,876 |  |  | 3,439 |  |  | 11.1 | % |  | — |  |  | — |  |  | 11.1 | %
International |  | 36,916 |  |  | 31,389 |  |  | 5,527 |  |  | 17.6 | % |  | 7.3 | % |  | — |  |  | 10.3 | %
LPD |  | 72,794 |  |  | 66,398 |  |  | 6,396 |  |  | 9.6 | % |  | 5.8 | % |  | — |  |  | 3.8 | %
United States |  | 7,264 |  |  | 7,019 |  |  | 245 |  |  | 3.5 | % |  | — |  |  | — |  |  | 3.5 | %
International |  | 65,530 |  |  | 59,379 |  |  | 6,151 |  |  | 10.4 | % |  | 6.5 | % |  | — |  |  | 3.8 | %
Other |  | 21,462 |  |  | 17,169 |  |  | 4,293 |  |  | 25.0 | % |  | 4.2 | % |  | — |  |  | 20.8 | %
Total Company |  | $ | 1,603,849 |  |  | $ | 1,263,928 |  |  | $ | 339,921 |  |  | 26.9 | % |  | 3.5 | % |  | 0.3 | % |  | 23.1 | %
United States |  | 987,876 |  |  | 802,781 |  |  | 185,095 |  |  | 23.1 | % |  | — |  |  | 0.3 | % |  | 22.7 | %
International |  | 615,973 |  |  | 461,147 |  |  | 154,826 |  |  | 33.6 | % |  | 9.6 | % |  | 0.3 | % |  | 23.6 | %

(1)Reported revenue growth and organic revenue growth may not recalculate due to rounding.
Total Company Revenu e. The increase in both U.S. and international organic revenues was driven by strong volume gains in CAG Diagnostics recurring revenue, reflecting continued high demand for companion animal diagnostics globally, supported by an increase in clinical visits and diagnostic utilization per clinical visit, as compared to the first half of 2020, which included the initial pandemic impacts. Our CAG Diagnostics instrument revenue reflects high placement volumes compared to the first half of the prior year, which was impacted by the global pandemic. The growth in our LPD business was primarily due to the demand for swine testing in China and occurred predominantly in the first quarter. The higher revenue in our Water business was primarily a result of the continued improvement in non-compliance testing that has been constrained during the pandemic and disruption in certain compliance testing during the second quarter of the prior year. The impact of currency movements increased total revenue by 3.5%.
40

The following table presents total Company results of operations:

|  | For the Six Months Ended June 30, |  | Change
Total Company - Results of Operations (dollars in thousands) |  | 2021 |  | Percent of Revenue |  | 2020 |  | Percent of Revenue |  | Amount |  | Percentage
Revenues |  | $ | 1,603,849 |  |  |  |  | $ | 1,263,928 |  |  |  |  | $ | 339,921 |  |  | 26.9 | %
Cost of revenue |  | 643,759 |  |  |  |  | 524,996 |  |  |  |  | 118,763 |  |  | 22.6 | %
Gross profit |  | 960,090 |  |  | 59.9 | % |  | 738,932 |  |  | 58.5 | % |  | 221,158 |  |  | 29.9 | %
Operating Expenses: |  |  |  |  |  |  |  |  |  |  |  |
Sales and marketing |  | 233,843 |  |  | 14.6 | % |  | 210,324 |  |  | 16.6 | % |  | 23,519 |  |  | 11.2 | %
General and administrative |  | 144,096 |  |  | 9.0 | % |  | 126,080 |  |  | 10.0 | % |  | 18,016 |  |  | 14.3 | %
Research and development |  | 75,276 |  |  | 4.7 | % |  | 64,955 |  |  | 5.1 | % |  | 10,321 |  |  | 15.9 | %
Total operating expenses |  | 453,215 |  |  | 28.3 | % |  | 401,359 |  |  | 31.8 | % |  | 51,856 |  |  | 12.9 | %
Income from operations |  | $ | 506,875 |  |  | 31.6 | % |  | $ | 337,573 |  |  | 26.7 | % |  | $ | 169,302 |  |  | 50.2 | %

Gross Profit. Gross profit increased due to higher sales volumes, as well as a 140 basis point increase in the gross profit margin. The increase in the gross profit margin was primarily due to volume leverage in our CAG Diagnostics recurring portfolio following the initial pandemic impacts in the first half of the prior year, price increases, and strong growth in veterinary software, services and diagnostic imaging recurring revenues. These increases were partially offset by product mix with higher CAG Diagnostics instrument revenue. The impact from foreign currency movements decreased the gross profit margin by less than 10 basis points, including the impact of hedge losses in the current year compared to hedge gains in the prior year.
Operating Expenses. Overall operating expenses were higher compared to the first half of 2020, during which cost containment efforts were implemented in response to the COVID-19 pandemic, including temporary reductions to compensation and benefits and travel costs. Sales and marketing expense increased primarily due to higher personnel-related costs, including investments in our global commercial capability, partially offset by lower travel costs. General and administrative expense increased primarily due to higher personnel-related costs, partially offset by an increase in the bad debt reserve during the first quarter of 2020. Research and development expense increased primarily due to higher project and personnel-related costs. The overall change in currency exchange rates increased operating expenses by approximately 2%.
41

Companion Animal Group
The following table presents revenue by product and service category for CAG:

|  | For the Six Months Ended June 30, |  |  |  |  |  |
Net Revenue (dollars in thousands) |  | 2021 |  | 2020 |  | Dollar Change |  | Reported Revenue Growth (1) |  | Percentage Change from Currency |  | Percentage Change from Acquisitions |  | Organic Revenue Growth (1)
CAG Diagnostics recurring revenue: |  | $ | 1,278,580 |  |  | $ | 998,179 |  |  | $ | 280,401 |  |  | 28.1 | % |  | 3.4 | % |  | 0.2 | % |  | 24.5 | %
IDEXX VetLab consumables |  | 502,444 |  |  | 384,774 |  |  | 117,670 |  |  | 30.6 | % |  | 4.4 | % |  | — |  |  | 26.2 | %
Rapid assay products |  | 153,498 |  |  | 122,088 |  |  | 31,410 |  |  | 25.7 | % |  | 1.5 | % |  | — |  |  | 24.2 | %
Reference laboratory diagnostic and consulting services |  | 569,456 |  |  | 449,077 |  |  | 120,379 |  |  | 26.8 | % |  | 3.0 | % |  | 0.4 | % |  | 23.4 | %
CAG diagnostics services and accessories |  | 53,182 |  |  | 42,240 |  |  | 10,942 |  |  | 25.9 | % |  | 4.2 | % |  | — |  |  | 21.7 | %
CAG Diagnostics capital - instruments |  | 66,244 |  |  | 42,704 |  |  | 23,540 |  |  | 55.1 | % |  | 5.4 | % |  | — |  |  | 49.8 | %
Veterinary software, services and diagnostic imaging systems |  | 93,538 |  |  | 77,213 |  |  | 16,325 |  |  | 21.1 | % |  | 1.1 | % |  | 2.8 | % |  | 17.2 | %
Net CAG revenue |  | $ | 1,438,362 |  |  | $ | 1,118,096 |  |  | $ | 320,266 |  |  | 28.6 | % |  | 3.3 | % |  | 0.4 | % |  | 25.0 | %

(1) Reported revenue growth and organic revenue growth may not recalculate due to rounding
CAG Diagnostics Recurring Revenue. We continue to see strong market demand for companion animal diagnostics globally across modalities, including high levels of growth in testing volumes following the initial pandemic impacts, which constrained volumes beginning in mid-March 2020 through May 2020. This volume growth includes an increase in clinical visits and diagnostic utilization per clinical visit. The increase in CAG Diagnostics recurring revenue was primarily due to increased volumes in IDEXX VetLab consumables, reference laboratory diagnostic services, and rapid assay products and, to a lesser extent, higher realized prices. The impact of currency movements increased revenue 3.4%.
The increase in IDEXX VetLab consumables revenue was primarily due to higher sales volumes for our Catalyst consumables and, to a lesser extent, ProCyte consumables. These increases were supported by an increase in testing utilization across regions, high customer retention levels, and expansion of our global premium instrument installed base.
The increase in rapid assay revenue resulted primarily from higher SNAP® 4Dx Plus sales volumes, as well as higher realized prices.
The increase in reference laboratory diagnostic and consulting services revenue was primarily due to higher testing volumes globally, as well as higher average unit sales prices. Acquisitions increased revenue by 0.4%.
The increase in CAG Diagnostics services and accessories revenue was primarily a result of the increase in our active installed base of instruments.
CAG Diagnostics Capital – Instrument Revenue. The increase in instrument revenue was primarily due to strong premium instrument placements globally, as compared to constrained placements in the first half of 2020, as a result of the global pandemic, due to restrictions on our sales professionals’ access to clinics and certain customers’ deferral of new instrument placements, which resulted in lower sales volumes.
Veterinary Software, Services and Diagnostic Imaging Systems Revenue. The increase in revenue was primarily due to increased veterinary software and diagnostic imaging subscription-based services due to the increases in our active installed base, new veterinary software system placements, and to a lesser extent, higher realized prices on these service offerings. Revenue also increased with higher imaging systems placements in the second quarter, specifically our ImageVue DR 30 platform, as compared to the second quarter of 2020 when diagnostic imaging placements were lower due to restriction on our
42

sales professionals’ access to clinic and certain customers deferring purchase decisions as a result of the COVID-19 pandemic. These favorable impacts were partially offset by a decrease in diagnostic imaging instrument revenue impacted by a reduction in earlier generation instrument platform sales. Acquisitions increased revenue 2.8%.
The following table presents the CAG segment results of operations:

|  | For the Six Months Ended June 30, |  | Change
Results of Operations (dollars in thousands) |  | 2021 |  | Percent of Revenue |  | 2020 |  | Percent of Revenue |  | Amount |  | Percentage
Revenues |  | $ | 1,438,362 |  |  |  |  | $ | 1,118,096 |  |  |  |  | $ | 320,266 |  |  | 28.6 | %
Cost of revenue |  | 584,702 |  |  |  |  | 474,286 |  |  |  |  | 110,416 |  |  | 23.3 | %
Gross profit |  | 853,660 |  |  | 59.3 | % |  | 643,810 |  |  | 57.6 | % |  | 209,850 |  |  | 32.6 | %
Operating Expenses: |  |  |  |  |  |  |  |  |  |  |  |
Sales and marketing |  | 213,442 |  |  | 14.8 | % |  | 192,098 |  |  | 17.2 | % |  | 21,344 |  |  | 11.1 | %
General and administrative |  | 127,038 |  |  | 8.8 | % |  | 109,136 |  |  | 9.8 | % |  | 17,902 |  |  | 16.4 | %
Research and development |  | 65,235 |  |  | 4.5 | % |  | 55,948 |  |  | 5.0 | % |  | 9,287 |  |  | 16.6 | %
Total operating expenses |  | 405,715 |  |  | 28.2 | % |  | 357,182 |  |  | 31.9 | % |  | 48,533 |  |  | 13.6 | %
Income from operations |  | $ | 447,945 |  |  | 31.1 | % |  | $ | 286,628 |  |  | 25.6 | % |  | $ | 161,317 |  |  | 56.3 | %

Gross Profit. Gross profit increased primarily due to higher sales volume, as well as a 170 basis point increase in the gross profit margin. The increase in the gross profit margin was primarily due to the benefit of volume leverage and price increases in our CAG Diagnostics recurring revenue portfolio, and strong growth in veterinary software, services and diagnostic imaging systems. These favorable factors were partially offset by product mix with higher CAG Diagnostics instrument revenue, as well as an impairment of rental assets in certain regions. The impact from foreign currency movements increased the gross profit margin by less than 10 basis points, including the impact of hedge losses in the current year compared to hedge gains in the prior year.
Operating Expenses. Overall operating expenses were higher compared to the first half of 2020, during which cost containment efforts were implemented in response to the COVID-19 pandemic, including temporary reductions to compensation and benefits and travel costs. Sales and marketing expense increased primarily due to higher personnel-related costs, including investments in our global commercial capability, partially offset by lower travel costs. General and administrative expense increased primarily due to higher personnel-related costs, partially offset by an increase in the bad debt reserve during the first quarter of 2020. Research and development expense increased primarily due to increased project and personnel-related costs. The overall change in currency exchange rates resulted in an increase in operating expenses by approximately 2%.
43

Water

The following table presents the Water segment results of operations:

|  | For the Six Months Ended June 30, |  | Change
Results of Operations (dollars in thousands) |  | 2021 |  | Percent of Revenue |  | 2020 |  | Percent of Revenue |  | Amount |  | Percentage
Revenues |  | $ | 71,231 |  |  |  |  | $ | 62,265 |  |  |  |  | $ | 8,966 |  |  | 14.4 | %
Cost of revenue |  | 22,019 |  |  |  |  | 17,838 |  |  |  |  | 4,181 |  |  | 23.4 | %
Gross profit |  | 49,212 |  |  | 69.1 | % |  | 44,427 |  |  | 71.4 | % |  | 4,785 |  |  | 10.8 | %
Operating Expenses: |  |  |  |  |  |  |  |  |  |  |  |
Sales and marketing |  | 8,457 |  |  | 11.9 | % |  | 7,773 |  |  | 12.5 | % |  | 684 |  |  | 8.8 | %
General and administrative |  | 6,620 |  |  | 9.3 | % |  | 6,689 |  |  | 10.7 | % |  | (69) |  |  | (1.0) | %
Research and development |  | 2,135 |  |  | 3.0 | % |  | 1,825 |  |  | 2.9 | % |  | 310 |  |  | 17.0 | %
Total operating expenses |  | 17,212 |  |  | 24.2 | % |  | 16,287 |  |  | 26.2 | % |  | 925 |  |  | 5.7 | %
Income from operations |  | $ | 32,000 |  |  | 44.9 | % |  | $ | 28,140 |  |  | 45.2 | % |  | $ | 3,860 |  |  | 13.7 | %

Revenue. The increase in our Water business was primarily a result of recovery in overall testing volumes, including continued improvement in non-compliance testing volume that has been constrained during the COVID-19 pandemic and disruptions in certain compliance testing areas, specifically during the second quarter of the prior year due to social distancing policies, including beach and pool closures, as well as price increases in our Colilert test products and related accessories used in coliform and E. coli testing. The impact of currency movements also increased revenue by 3.7%.
Gross Profit. Gross profit increased due to higher sales volumes despite a 230 basis point decrease in the gross profit margin, which reflected a 120 basis point reduction due to foreign currency movements, including the impact of hedge losses in the current year compared to hedge gains in the prior year. The gross profit margin was further reduced by higher product and distribution costs. These reductions in the gross profit margin were partially offset by the net benefit of price increases.
Operating Expenses. Overall operating expenses were higher compared to the first half of 2020, during which cost containment efforts were implemented in response to the COVID-19 pandemic, including temporary reductions to compensation and benefits and travel costs. Sales and marketing expense increased primarily due to higher personnel-related costs. Research and development expense increased primarily due to higher third-party costs. The overall change in currency exchange rates resulted in an increase in operating expenses of approximately 2%.
44

Livestock, Poultry and Dairy

The following table presents the LPD segment results of operations:

|  | For the Six Months Ended June 30, |  | Change
Results of Operations (dollars in thousands) |  | 2021 |  | Percent of Revenue |  | 2020 |  | Percent of Revenue |  | Amount |  | Percentage
Revenues |  | $ | 72,794 |  |  |  |  | $ | 66,398 |  |  |  |  | $ | 6,396 |  |  | 9.6 | %
Cost of revenue |  | 26,387 |  |  |  |  | 25,247 |  |  |  |  | 1,140 |  |  | 4.5 | %
Gross profit |  | 46,407 |  |  | 63.8 | % |  | 41,151 |  |  | 62.0 | % |  | 5,256 |  |  | 12.8 | %
Operating Expenses: |  |  |  |  |  |  |  |  |  |  |  |
Sales and marketing |  | 10,680 |  |  | 14.7 | % |  | 9,680 |  |  | 14.6 | % |  | 1,000 |  |  | 10.3 | %
General and administrative |  | 8,579 |  |  | 11.8 | % |  | 8,167 |  |  | 12.3 | % |  | 412 |  |  | 5.0 | %
Research and development |  | 6,472 |  |  | 8.9 | % |  | 5,392 |  |  | 8.1 | % |  | 1,080 |  |  | 20.0 | %
Total operating expenses |  | 25,731 |  |  | 35.3 | % |  | 23,239 |  |  | 35.0 | % |  | 2,492 |  |  | 10.7 | %
Income from operations |  | $ | 20,676 |  |  | 28.4 | % |  | $ | 17,912 |  |  | 27.0 | % |  | $ | 2,764 |  |  | 15.4 | %

Reve nue. The favorable impact of foreign currency movements increased revenue by 5.8%. Excluding the impact of currency, overall revenues increased primarily due to higher demand for diagnostic testing in China, during the first quarter of 2021, and higher bovine testing volumes in Europe and the Americas, as compared to pandemic impacts in the second quarter of the prior year. Beginning in the second quarter of 2021 we saw lower livestock testing volumes in China, as swine herds are rebuilt, pork prices are low, and government requirements change related to live animal imports and livestock infectious disease programs, in comparison to high prior-year demand for African Swine Fever testing. We anticipate these trends will continue to impact our revenues in China during the second half of 2021.
Gross Profit. The increase in gross profit was primarily due to higher sales volumes and a 180 basis point increase in the gross profit margin. The increase in the gross profit margin is primarily due to volume leverage and favorable product mix, partially offset by lower realized prices and the impact from foreign currency movements, which decreased gross profit margin by approximately 100 basis points, including the impact of hedge losses in the current year compared to hedge gains in the prior year.
Operating Expens es. Overall operating expenses were higher compared to the first half of 2020, during which cost containment efforts were implemented in response to the COVID-19 pandemic, including temporary reductions to compensation and benefits, and travel costs. Sales and marketing expense increased primarily due to higher travel and personnel-related costs. General and administrative expenses increased primarily due to higher personnel-related costs, partially offset an increase in the bad debt reserve during the first half of 2020. Research and development expense increased primarily due to higher personnel-related costs and third-party development costs, partially offset by leveraging LPD personnel to support our human COVID testing products. The overall change in currency exchange rates resulted in an increase in operating expenses of approximately 3%.
45

Other
The following table presents the Other results of operations:

|  | For the Six Months Ended June 30, |  | Change
Results of Operations (dollars in thousands) |  | 2021 |  | Percent of Revenue |  | 2020 |  | Percent of Revenue |  | Amount |  | Percentage
Revenues |  | $ | 21,462 |  |  |  |  | $ | 17,169 |  |  |  |  | $ | 4,293 |  |  | 25.0 | %
Cost of revenue |  | 10,651 |  |  |  |  | 7,625 |  |  |  |  | 3,026 |  |  | 39.7 | %
Gross profit |  | 10,811 |  |  | 50.4 | % |  | 9,544 |  |  | 55.6 | % |  | 1,267 |  |  | 13.3 | %
Operating Expenses: |  |  |  |  |  |  |  |  |  |  |  |
Sales and marketing |  | 1,264 |  |  | 5.9 | % |  | 773 |  |  | 4.5 | % |  | 491 |  |  | 63.5 | %
General and administrative |  | 1,859 |  |  | 8.7 | % |  | 2,088 |  |  | 12.2 | % |  | (229) |  |  | (11.0 | %)
Research and development |  | 1,434 |  |  | 6.7 | % |  | 1,790 |  |  | 10.4 | % |  | (356) |  |  | (19.9 | %)
Total operating expenses |  | 4,557 |  |  | 21.2 | % |  | 4,651 |  |  | 27.1 | % |  | (94) |  |  | (2.0 | %)
Income from operations |  | $ | 6,254 |  |  | 29.1 | % |  | $ | 4,893 |  |  | 28.5 | % |  | $ | 1,361 |  |  | 27.8 | %

Revenue. The increase in revenue was primarily due to our OPTI COVID-19 PCR testing products and services, which were introduced in the second quarter of 2020, as well as higher OPTI Medical consumables. We currently estimate that the future demand for our OPTI COVID-19 PCR testing products and services will be lower than prior periods, although it is difficult to project given the uncertain nature of the COVID-19 pandemic, including the spread of variants, rates of vaccinations, governmental and private institution testing requirements, and alternative suppliers. The impact of currency movements increased revenue by 4.2%.
Gross Profit. The increase in gross profit was primarily due to higher sales volumes of our OPTI COVID-19 PCR testing products and services, primarily in the first quarter of 2021. The gross profit margin decreased 520 basis points primarily due to higher product costs associated with write-downs of excess COVID-19 testing inventory in the second quarter of 2021. The overall change in currency exchange rates had an immaterial impact on gross profit.
Operating Expenses. Sales and marketing expense increased primarily due to higher personnel-related costs associated with our OPTI COVID-19 PCR product and services. General and administrative expense decreased primarily due to lower foreign exchange losses on settlements of foreign currency denominated transactions, as compared to the prior year, for all operating segments, which are reported within our Other segment. Research and development expense decreased primarily due to lower project costs associated with the development of the OPTI COVID-19 PCR test.
Non-Operating Items
Interest Expense. Interest ex pense was $15.2 million f or the six months ended June 30, 2021, as compared to $17.2 million for the same period in the prior year. The decrease in interest expense was primarily the result of lower average debt levels.
Provision for Income Taxes. Our effective income tax rate was 17.3% for the six months ended June 30, 2021, as compared to 18.6% for the six months ended June 30, 2020. The decrease in our effective tax rate as compared to the same period in the prior year, was primarily driven by an overall increase in tax benefits from share-based compensation.
46

Liquidity and Capital Resources
We fund the capital needs of our business through cash on hand, funds generated from operations, proceeds from long-term senior note financings, and amounts available under our Credit Facility. At June 30, 2021, we had $232.1 million of cash and cash equivalents, as compared to $383.9 million on December 31, 2020. Working capital totaled $349.4 million at June 30, 2021, as compared to $480.0 million at December 31, 2020. Additionally, at June 30, 2021, we had remaining borrowing availability of $998.6 million under our $1 billion Credit Facility, with no outstanding borrowings on the Credit Facility. The general availability of funds under our Credit Facility is reduced by $1.4 million for outstanding letters of credit. We believe that, if necessary, we could obtain additional borrowings to fund our growth objectives. We further believe that current cash and cash equivalents, funds generated from operations, and committed borrowing availability will be sufficient to fund our operations, capital purchase requirements, and anticipated growth needs for the next twelve months. We believe that these resources, coupled with our ability, as needed, to obtain additional financing, will also be sufficient to fund our business as currently conducted for the foreseeable future. We may enter into new financing arrangements or refinance or retire existing debt in the future depending on market conditions. Should we require more capital in the U.S. than is generated by our operations, for example to fund significant discretionary activities, we could elect to raise capital in the U.S. through the incurrence of debt or equity issuances, which we may not be able to complete on favorable terms or at all. In addition, these alternatives could result in increased interest expense or other dilution of our earnings.
We manage our worldwide cash requirements considering available funds among all of our subsidiaries. Our foreign cash and marketable securities are generally available without restrictions to fund ordinary business operations outside the U.S.
The following table presents cash, cash equivalents, and marketable securities held domestically and by our foreign subsidiaries:

Cash, cash equivalents and marketable securities (dollars in millions) |  | June 30, 2021 |  | December 31, 2020
U.S. |  | $ | 94.2 |  |  | $ | 248.4 |
Foreign |  | 137.9 |  |  | 135.5 |
Total |  | $ | 232.1 |  |  | $ | 383.9 |
Total cash, cash equivalents, and marketable securities held in U.S. dollars by our foreign subsidiaries |  | $ | 4.9 |  |  | $ | 18.0 |

Of the $232.1 million of cash and cash equivalents held as of June 30, 2021, greater than 99% was held as bank deposits.
The following table presents additional key information concerning working capital:

| For the Three Months Ended
| June 30, 2021 |  | March 31, 2021 |  | December 31, 2020 |  | September 30, 2020 |  | June 30, 2020
Days sales outstanding(1) | 42.2 |  |  | 41.8 |  |  | 42.2 |  |  | 41.5 |  |  | 44.4 |
Inventory turns(2) | 2.1 |  |  | 2.0 |  |  | 2.1 |  |  | 1.9 |  |  | 1.6 |

(1) Days sales outstanding represents the average of the accounts receivable balances at the beginning and end of each quarter divided by revenue for that quarter, the result of which is then multiplied by 91.25 days.
(2) Inventory turns represent inventory-related cost of product revenue for the 12 months preceding each quarter-end divided by the average inventory balances at the beginning and end of each quarter.
47

Sources and Uses of Cash
The following table presents cash provided (used):

|  | For the Six Months Ended June 30,
(in thousands) |  | 2021 |  | 2020 |  | Dollar Change
Net cash provided by operating activities |  | $ | 358,377 |  |  | $ | 236,013 |  |  | $ | 122,364 |
Net cash used by investing activities |  | (199,250) |  |  | (74,226) |  |  | (125,024) |
Net cash used by financing activities |  | (309,868) |  |  | (144,630) |  |  | (165,238) |
Net effect of changes in exchange rates on cash |  | (1,053) |  |  | (2,190) |  |  | 1,137 |
Net change in cash and cash equivalents |  | $ | (151,794) |  |  | $ | 14,967 |  |  | $ | (166,761) |

Operating Activities. The increase in cash provided by operating activities of $122.4 million was driven primarily by an increase in net income. The following table presents cash flow impacts from changes in operating assets and liabilities:

|  | For the Six Months Ended June 30,
(in thousands) |  | 2021 |  | 2020 |  | Dollar Change
Accounts receivable |  | $ | (50,721) |  |  | $ | (57,277) |  |  | $ | 6,556 |
Inventories |  | (20,412) |  |  | (29,254) |  |  | 8,842 |
Accounts payable |  | 3,812 |  |  | (6,729) |  |  | 10,541 |
Deferred revenue |  | (5,037) |  |  | (6,695) |  |  | 1,658 |
Other assets and liabilities |  | (55,162) |  |  | 4,540 |  |  | (59,702) |
Total change in cash due to changes in operating assets and liabilities |  | $ | (127,520) |  |  | $ | (95,415) |  |  | $ | (32,105) |

Cash used due to changes in operating assets and liabilities during the six months ended June 30, 2021, as compared to the same period in the prior year, increased by approximately $32.1 million. The increase in use of cash in other assets and liabilities was due to higher income taxes paid in the current year, as compared to the same period in 2020, as the U.S. federal and state payments in the prior year were delayed until the third quarter of 2020 under the COVID-19 stimulus guidance. The use of cash in other assets and liabilities was further increased by higher incentive payments in 2021, as compared to 2020, and higher investments in customer volume commitment programs to support instrument placements, partially offset by higher non-cash operating expenses recorded as accrued liabilities, including employee incentive programs. The increase in cash provided by accounts payable over the same period in the prior-year was due to higher investment activity to support growth in the current period. The increase in cash provided by accounts receivable over the same prior-year period was due to higher growth at the end of the second quarter of 2020, as sales volumes began to rebound at the end of the quarter due to pent-up demand from the beginning of the COVID-19 pandemic, as well as improved aging of accounts receivable in the current period. Cash used to purchase inventory in the current period, as compared to the prior period, was lower primarily due to the timing of inventory payments.
We have historically experienced proportionally lower net cash flows from operating activities during the first quarter and proportionally higher cash flows from operating activities for the remainder of the year driven primarily by payments related to annual employee incentive programs in the first quarter following the year for which the bonuses were earned.
Investing Activities. Cash used by investing activities was $199.3 million for the six months ended June 30, 2021, as compared to $74.2 million for the same period in the prior year. The increase in cash used by investing activities was primarily due to the acquisition of ezyVet, partially offset by lower capital expenditures due to the completion of certain major facilities projects during 2020.
We are increasing our outlook for full year capital spending to a range of $150 million to $160 million for 2021. The projected increase in capital spend will support manufacturing and distribution growth capacity and is expected to include approximately $20 million in real estate purchases.
Financing Activities. Cash used by financing activities was $309.9 million for the six months ended June 30, 2021, as compared to $144.6 million of cash used for the same period in the prior year. The increase in cash used by financing activities was due to an increase in repurchases of our common stock in the current period as compared to the same period in the prior
48

year when we suspended repurchases due to the COVID-19 pandemic. During the first six months of 2020, the issuance of senior notes, partly offset by repayments on our Credit Facility provided $32.3 million in cash.
Cash used to repurchase shares of our common stock increased $138.0 million during the six months ended June 30, 2021. We believe that the repurchase of our common stock is a favorable means of returning value to our stockholders, and we also repurchase our stock to offset the dilutive effect of our share-based compensation programs. Repurchases of our common stock may vary depending upon the level of other investing activities and the share price. See Note 11 to the unaudited condensed consolidated financial statements in Part I. Item 1. of this Quarterly Report on Form 10-Q for additional information about our share repurchases.
There was no net activity under our Credit Facility during the six months ended June 30, 2021, as compared to $167.7 million of net repayments in the same period of the prior year. At June 30, 2021, we had no outstanding borrowings under the Credit Facility. The obligations under our Credit Facility may be accelerated upon the occurrence of an event of default under the Credit Facility, which includes customary events of default including payment defaults, defaults in the performance of the affirmative, negative and financial covenants, the inaccuracy of representations or warranties, bankruptcy and insolvency-related defaults, defaults relating to judgments, certain events related to employee pension benefit plans under the Employee Retirement Income Security Act of 1974 (“ERISA”), the failure to pay specified indebtedness, cross-acceleration to specified indebtedness, and a change of control default.
The Credit Agreement contains affirmative, negative, and financial covenants customary for financings of this type. The negative covenants include restrictions on liens, indebtedness of subsidiaries of the Company, fundamental changes, investments, transactions with affiliates, certain restrictive agreements, and sanctions laws and regulations. The financial covenant is a consolidated leverage ratio test.
As of June 30, 2021, the aggregate principal amounts of two series of our outstanding senior notes will become due and payable over the next twelve months: our 2021 Series A Notes for $50 million, which became due on July 21, 2021, and our 2022 Series A Notes for $75 million, which will be due on February 12, 2022. On July 21, 2021, we paid off our 2021 Series A Notes with cash provided by operations, and we anticipate paying off our 2022 Series A Notes when due and payable with cash provided by operations. Should we elect to prepay any of our senior notes, such aggregate prepayment will include the applicable make-whole amount(s), as defined within the applicable Senior Note Agreements. Additionally, in the event of a change in control of the Company or upon the disposition of certain assets of the Company the proceeds of which are not reinvested (as defined in the Senior Note Agreements), we may be required to prepay all or a portion of the senior notes. The obligations under the senior notes may be accelerated upon the occurrence of an event of default under the applicable Senior Note Agreements, each of which includes customary events of default including payment defaults, defaults in the performance of the affirmative, negative and financial covenants, the inaccuracy of representations or warranties, bankruptcy and insolvency-related defaults, defaults relating to judgments, certain events related to employee pension benefit plans under ERISA, the failure to pay specified indebtedness, and cross-acceleration to specified indebtedness.
Effect of Currency Translation on Cash. The net effect of changes in foreign currency exchange rates is related to changes in exchange rates between the U.S. dollar and the functional currencies of our foreign subsidiaries. These changes will fluctuate for each period presented as the value of the U.S. dollar relative to the value of the foreign currencies changes. A currency’s value depends on many factors, including interest rates and the country’s debt levels and strength of economy.
Off-Balance Sheet Arrangements. We have no off-balance sheet arrangements or variable interest entities, except for letters of credit and third-party guarantees.
49

Financial Covenant. The sole financial covenant of our Credit Facility and Senior Note Agreements is a consolidated leverage ratio test that requires our ratio of debt to earnings before interest, taxes, depreciation and amortization, non-recurring transaction expenses incurred in connection with acquisitions, share-based compensation expense, and certain other non-cash losses and charges (“Adjusted EBITDA”) not to exceed 3.5-to-1. At June 30, 2021, we were in compliance with such covenant. The following details our consolidated leverage ratio calculation:

(in thousands) | Twelve months ended
Trailing 12 Months Adjusted EBITDA: | June 30, 2021
Net income attributable to stockholders (as reported) | $ | 727,848 |
Interest expense | 31,135 |
Provision for income taxes | 105,037 |
Depreciation and amortization | 99,646 |
Acquisition-related expense | 2,054 |
Share-based compensation expense | 34,382 |
Extraordinary and other non-recurring non-cash charges | 5,911 |
Adjusted EBITDA | $ | 1,006,013 |
(in thousands) |
Debt to Adjusted EBITDA Ratio: | June 30, 2021
Line of credit | $ | — |
Current and long-term portions of long-term debt | 905,061 |
Total debt | 905,061 |
Acquisition-related contingent consideration payable | 6,608 |
Financing leases | 19 |
Deferred financing costs | 573 |
Gross debt | $ | 912,261 |
Gross debt to Adjusted EBITDA ratio | 0.91 |
Less: Cash and cash equivalents | $ | 232,134 |
Net debt | $ | 680,127 |
Net debt to Adjusted EBITDA ratio | 0.68

Adjusted EBITDA, gross debt, net debt, gross debt to Adjusted EBITDA ratio and net debt to Adjusted EBITDA ratio are non-GAAP financial measures which should be considered in addition to, and not as a replacement for, financial measures presented according to U.S. GAAP. Management believes that reporting these non-GAAP financial measures provides supplemental analysis to help investors further evaluate our business performance and available borrowing capacity under our Credit Facility.
Other Commitments, Contingencies and Guarantees
Significant commitments, contingencies and guarantees at June 30, 2021, are described in Note 15 to the unaudited condensed consolidated financial statements in Part I. Item 1. of this Quarterly Report on Form 10-Q.
50

Item 3. Quantitative and Qualitative Disclosures About Market Risk
For quantitative and qualitative disclosures about market risk affecting us, see the section under the heading “Part II. Item 7A. Quantitative and Qualitative Disclosure About Market Risk” of our 2020 Annual Report. As of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the market risks described in our 2020 Annual Report, except for the impact of foreign exchange rates, as discussed below.
Foreign Currency Exchange Impact s. Approximately 22% and 23% of our consolidated revenue was derived from products manufactured in the U.S. and sold internationally in local currencies for the three and six months ended June 30, 2021, respectively, as compared to 20% and 21% for the three and six months ended June 30, 2020, respectively. Strengthening of the U.S. dollar exchange rate relative to other currencies has a negative impact on our revenues derived in currencies other than the U.S. dollar and on profits of products manufactured in the U.S. and sold internationally, and a weakening of the U.S. dollar has the opposite effect. Similarly, to the extent that the U.S. dollar is stronger in current or future periods relative to the exchange rates in effect in the corresponding prior periods, our growth rate will be negatively affected. The impact of foreign currency denominated costs and expenses and foreign currency denominated supply contracts partly offsets this exposure. Additionally, our designated hedges of intercompany inventory purchases and sales help delay the impact of certain exchange rate fluctuations on non-U.S. dollar denominated revenues.
Our foreign currency exchange impacts are comprised of three components: 1) local currency revenues and expenses; 2) the impact of hedge contracts; and 3) intercompany and monetary balances for our subsidiaries that are denominated in a currency that is different from the functional currency used by each subsidiary. Based on projected revenues and expenses for the remainder of 2021, excluding the impact of intercompany and trade balances denominated in currencies other than the functional subsidiary currencies, we project a 1% strengthening of the U.S. dollar would reduce revenue by approximately $6 million and operating income by approximately $3 million. Additionally, we project our foreign currency hedge contracts in place as of June 30, 2021, would result in incremental offsetting gains of approximately $1 million. The impact of the intercompany and trade balances, and monetary balances referred to in the third component above have been excluded, as they are transacted at multiple times during the year and we are not able to reliably forecast the impact that changes in exchange rates would have on such balances.
At our current foreign currency exchange rate assumptions, we anticipate the effect of a weaker U.S. dollar for the remainder of the year will have a favorable impact on our operating results by increasing our revenues, operating profit, and diluted earnings per share for the remainder of the year ending December 31, 2021, by approximately $4 million, $1 million, and $0.01 per share, respectively. This favorable currency impact includes foreign currency hedging activity, which is expected to decrease total Company operating profit by less than $0.5 million and no impact to diluted earnings for the remainder of the year ended December 31, 2021. The actual impact of changes in the value of the U.S. dollar against foreign currencies in which we transact may materially differ from our expectations described above. The above estimates assume that the value of the U.S. dollar will reflect the euro at 1.17, the British pound at 1.37, the Canadian dollar at 0.79, and the Australian dollar at 0.73; and the Japanese yen at ¥112, the Chinese renminbi at RMB 6.56 and the Brazilian real at R$5.33 relative to the U.S. dollar for the remainder of 2021.
51

The following table presents the estimated foreign currency exchange impact on our revenues, operating profit, and diluted earnings per share for the current period and as compared to the respective prior-year period:

|  | For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(in thousands, except per share amounts) |  | 2021 |  | 2020 |  | 2021 |  | 2020
Revenue impact |  | $ | 25,280 |  |  | $ | (7,493) |  |  | $ | 44,714 |  |  | $ | (14,050) |
Operating profit impact, excluding hedge activity and exchange impacts on settlement of foreign currency denominated transactions |  | $ | 14,169 |  |  | $ | (4,275) |  |  | $ | 25,930 |  |  | $ | (6,609) |
Hedge (losses) gains - current period |  | (2,715) |  |  | 1,812 |  |  | (5,145) |  |  | 3,153 |
Exchange (losses) gains on settlements of foreign currency denominated transactions - current period |  | (854) |  |  | 799 |  |  | (924) |  |  | (1,108) |
Operating profit impact - current period |  | $ | 10,600 |  |  | $ | (1,664) |  |  | $ | 19,861 |  |  | $ | (4,564) |
Hedge (gains) - prior period |  | (1,812) |  |  | (2,509) |  |  | (3,153) |  |  | (3,920) |
Exchange (gains) losses on settlement of foreign currency denominated transactions - prior period |  | (799) |  |  | 318 |  |  | 1,108 |  |  | 541 |
Operating profit impact - as compared to prior period |  | $ | 7,989 |  |  | $ | (3,855) |  |  | $ | 17,816 |  |  | $ | (7,943) |
Diluted earnings per share impact - as compared to prior period |  | $ | 0.07 |  |  | $ | (0.04) |  |  | $ | 0.16 |  |  | $ | (0.07) |

52

Item 4. Controls and Procedures
Disclosure Controls and Procedures
Our management is responsible for establishing and maintaining disclosure controls and procedures, as defined by the SEC in its Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 as amended (the “Exchange Act”). The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act are recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures at June 30, 2021, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended June 30, 2021, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II — OTHER INFORMATION
Item 1. Legal Proceedings
Due to the nature of our activities, we are at times subject to pending and threatened legal actions that arise out of the ordinary course of business. In the opinion of management, based in part upon advice of legal counsel, the disposition of any such currently pending matters is not expected to have a material effect on our results of operations, financial condition, or cash flows. However, the results of legal actions cannot be predicted with certainty. Therefore, it is possible that our results of operations, financial condition, or cash flows could be materially adversely affected in any particular period by the unfavorable resolution of one or more legal actions.
Item 1A. Risk Factors
In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors discussed in “Part I. Item 1A. Risk Factors” in our 2020 Annual Report, which could materially affect our business, financial condition, or future results. There have been no material changes from the risk factors previously disclosed in the 2020 Annual Report. The risks described in our 2020 Annual Report are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, or future results.
53

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
During the three months ended June 30, 2021, we repurchased shares of common stock as described below:

Period |  | Total Number of Shares Purchased (a) |  | Average Price Paid per Share (b) |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1) (c) |  | Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs (1) (d)
April 1 to April 30, 2021 |  | 88,100 |  |  | $ | 524.31 |  |  | 88,100 |  |  | 5,910,283 |
May 1 to May 31, 2021 |  | 126,974 |  |  | $ | 534.50 |  |  | 126,974 |  |  | 5,783,309 |
June 1 to June 30, 2021 |  | 126,204 |  |  | $ | 588.87 |  |  | 126,199 |  |  | 5,657,110 |
Total |  | 341,278 |  | (2) | $ | 551.98 |  |  | 341,273 |  |  | 5,657,110 |

The total shares repurchased include shares surrendered for employee statutory tax withholding. See Note 11 to the unaudited condensed consolidated financial statements in Part I. Item 1. of this Quarterly Report on Form 10-Q for additional information about our share repurchases.
(1)On August 13, 1999, our Board of Directors approved and announced the repurchase of our common stock in the open market or in negotiated transactions pursuant to the Company’s share repurchase program. The authorization has been increased by the Board of Directors on numerous occasions; most recently, on February 12, 2020, the maximum level of shares that may be repurchased under the program was increased from 68 million to 73 million shares. There is no specified expiration date for this share repurchase program. There were no other repurchase programs outstanding during the three months ended June 30, 2021, and no share repurchase programs expired during the period. There were 341,273 share repurchases made during the three months ended June 30, 2021, in transactions made pursuant to our share repurchase program.
(2)During the three months ended June 30, 2021, we received 5 shares of our common stock that were surrendered by employees in payment for the minimum required withholding taxes due on the vesting of restricted stock units and settlement of deferred stock units. In the above table, these shares are included in columns (a) and (b), but excluded from columns (c) and (d). These shares do not reduce the number of shares that may yet be purchased under the share repurchase program.
54

Item 6. Exhibits

Exhibit No. | Description
31.1 | Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 | Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101 | The following financial and related information from IDEXX Laboratories, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, formatted in Inline eXtensible Business Reportable Language (iXBRL) includes: (i) the Condensed Consolidated Balance Sheet; (ii) the Condensed Consolidated Statement of Income; (iii) the Condensed Consolidated Statements of Comprehensive Income; (iv) the Condensed Consolidated Statement of Changes in Stockholders' Equity; (v) the Condensed Consolidated Statement of Cash Flows; and, (vi) Notes to Consolidated Financial Statements.
104 | The cover page from the Company's Quarterly Report of Form 10-Q for the quarter ended June 30, 2021, formatted in Inline XBRL and contained in Exhibit 101.

55

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

| IDEXX LABORATORIES, INC.
| /s/ Brian P. McKeon
Date: July 30, 2021 | Brian P. McKeon
| Executive Vice President, Chief Financial Officer and Treasurer
| (Principal Financial Officer)

56